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SUMMARY 
 
Psychological treatments occupy an important place in evidence-based mental health 
treatments. It is an exciting time to fuel treatment research: there is a pressing demand for 
improvements poised alongside new opportunities afforded by closer links with sister scientific 
and clinical disciplines. The needs are great. Even our best treatments do not work for 
everyone, there are many mental health problems for which treatments have not been 
developed, and the implementation of treatments needs to address worldwide scalability. 
Meanwhile, psychological treatments are yet to benefit from numerous recent innovations in 
science, and arguably vice versa. We discuss opportunities for future research efforts to 
improve psychological treatments. Ripe areas of enquiry include (1) understanding underlying 
mechanisms; (2) increasing access worldwide; (3) developing cross-modal combination 
treatment approaches; and (4) enhancing a preventative focus and developmental approach. We 
need to (5) harness new technologies; (6) improve trials methodology; and (7) improve training 
in interdisciplinary mental health sciences. Psychological treatments should target challenges 
such as (8) the inherent complexities of mental health disorders and (9) suicide prevention. The 
challenges to which a psychological perspective can contribute will require genuine innovation 
(10). Improving psychological treatments presents an exciting prospect for scientists and 
clinicians interested in the ‘science of mental life’.   
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INTRODUCTION 
 
Psychology and Psychological Treatments 
Psychology from its inception was defined as ‘the science of mental life’1. 
Psychological treatments have evolved to occupy a key place in evidence-based treatments for 
mental health. Pivotal techniques used in today’s evidence-based psychological treatments 
arose from psychological research on processes in the 1950s and 1960s, with basic and clinical 
researchers often in the same department. In recent decades the treatment field has drifted away 
from its scientific roots, while mechanistic studies have drifted further away from treatment 
issues. Now is the time for greater synergy to invigorate psychological treatment research2. 
Psychological treatments offer great promise for continued innovation – arguably now more 
than ever before – not least due to the development of scientific methods and perspectives from 
the numerous allied fields that can be drawn upon. 
While researchers and industry struggle to produce new drugs for mental disorders 
footnote #1, psychological treatments may have the potential to deliver acceptable, effective, and 
safe treatment options more quickly3. Building bridges between psychological treatment and 
other modalities such as via combination approaches could also benefit many. But it will not be 
easy. New trials of psychological treatments are greeted not only with enthusiasm, but also 
controversy. Questions are constantly being raised about trial design, implementation, and 
interpretation. Do trial populations reflect real clinical populations? What is an appropriate 
control group? At what point should trial evidence be translated into day-to-day practice? How 
can an intervention be disseminated nationally and internationally? Current assumptions are 
also being queried. Is single-session therapy feasible? Is one, consistent therapist an optimal or 
even necessary component of psychological treatment? How can new technologies best be 
harnessed? 
 
A core role for psychological treatments in the future requires a research agenda 
                                                          
footnote #1The terms mental disorder, mental health disorder, psychological disorder, psychiatric 
disorder, mental health problem and so forth are used interchangeably throughout this 
document. We recognise wider psychological treatments terminology such as mental health 
difficulties, behavioural difficulties and so forth. 
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As we argue below, the burden of mental disorders is enormous, and yet current 
pharmacological and psychological treatments offer only limited effects for reducing disease 
burden. Since the majority of patients prefer psychological treatments over pharmacological 
treatments4, increased research efforts are required to evolve psychological treatments to the 
level of significant impact upon mental disease burden worldwide. But in order to realize the 
development of psychological treatments, a research agenda is needed that can guide this field 
for the coming years2.   
 
 
 
Methodology and approach employed in preparing this commission 
This commission arose from an initial consultation meeting at The Lancet’s London 
Wall office in December, 2015, in which researchers from a variety of backgrounds with 
interests and/or expertise in psychological treatments research met to discuss challenges in the 
field, and to lay out possibilities for a future research agenda for advancing the science of 
psychological treatments. The group’s common interest was captured by Kazdin’s call to arms 
to “reboot psychotherapy research and practice to reduce the burden of mental illness”5.  
Attendees’ backgrounds in terms of subject disciplines included clinical psychology, 
psychiatry, neuroscience, experimental psychology and pharmacology. The language of the 
meeting was English, and attendees were from the UK, Europe and USA, and we have only 
cited papers that have been published in English. The commission expresses the authors’ 
collective views about some of the key areas in which we see scope for improvements in the 
field. It was not our goal to provide an exhaustive literature review, nor a systematic review of 
specific topics. Rather, we have cited sources that are relevant to the issues that we have 
discussed in the context of each of the ten themes. We note that there continue to be many more 
important topic areas and perpsectives, and that this is a start for necessary and continued 
discussion.  
 
“By the end of 2015, representatives of the leading clinical and 
neuroscience bodies should meet to hammer out the ten most pressing 
research questions for psychological treatments. This list should be 
disseminated to granting agencies, scientists, clinicians and the public 
internationally…reconsider the proportion of investments in mental health 
relative to other diseases.” 2 
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 The commission is comprised of ten subsections, each of which contains a theme that 
we consider critical to the development and improvement of research on psychological 
treatments. The content of these ten sections is as follows: mechanisms of psychological 
treatments, deployment of psychological treatments, cross-modal treatment approaches, 
prevention and early intervention, the role of technology in psychological treatments, evaluating 
psychological treatments, interdisciplinary training, complexity of mental health problems, 
suicidal behaviour, and finally, future directions in the development and innovation of 
psychological treatments.” 
 
Mental health disorders are widespread and costly 
Every year almost one in five people worldwide suffer from a mental disorder6, and 
more than 750,000 people die by suicide7. In 2010, mental and substance use disorders 
accounted for 183.9 million disability-adjusted life years (DALYs,8), with most disease burden 
caused by depressive disorders, anxiety disorders and substance-use disorders. These numbers 
are likely to be underestimates given that it is assumed in these calculations that mental 
disorders are not associated with excess mortality, except suicide. There is increasing evidence, 
however, that people with a mental disorder have a considerably higher risk of dying earlier 
than those without mental disorders9. Between 1990 and 2010 the disease burden of mental and 
substance use disorders increased by more than 35%, mostly driven by population growth and 
ageing8. 
 Apart from the personal suffering of affected patients and their families, mental 
disorders pose enormous economic challenges to communities and societies in terms of 
production losses and health and social care expenditures10-12. The global cost of mental health 
conditions in 2010 has been estimated at US$ 2.5 trillion, and these costs are expected to grow 
to US$ 6.0 trillion by 203013. It is for this reason that conceptualizations of mental health need 
to expand beyond the notions of disease or infirmity to functionally related outcomes, or more 
broadly speaking, the ability to adapt and to self-manage14. 
Current treatments make as yet a limited contribution to the reduction of the disease burden 
Several evidence-based biological and psychological treatments are available for a range 
of mental health disorders. There is, however, room for considerable improvement. Current 
treatments are estimated to be able to reduce the disease burden by only approximately 40% and 
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that is only under optimal conditions, when all patients with a mental illness receive an 
evidence-based treatment15. Coverage (i.e., the proportion of people who receive a consultation 
for a mental disorder) is however typically much lower than 100%, is hardly above 50% for any 
disorder in any country, and for some disorders (e.g., alcohol-related disorders) is below 10%. 
We note that, according to the Adult Psychiatric Morbidity Survey conducted in 2014, there has 
been a welcome increase in people with common mental health disorders receiving treatment, 
although it is notable that this increase can largely be attributed to the use of psychotropic 
medication16. It is also well-known that the majority of patients treated for mental health 
disorders do not receive evidence-based treatments but rather receive a wide array of treatments 
including interventions with no evidence-base17.  
Patient preference for psychological treatment options alongside restricted availability 
Many patients with mental disorders in high-income countries receive drug treatments, 
and these numbers are increasing. For example, in the United States the use of antidepressants 
has almost doubled between 1996 and 200518, from a rate of 5.84% to 10.12% (or from 13 to 27 
million individuals). From 1999 to 2010, on average 8.6% of adult depression visits included 
the prescription of a Second-Generation Antipsychotic19 – this rate doubled during this period 
from 4.6% to 12.5%. An increasing proportion of patients receive psychotropic medication 
without psychotherapy20. Meanwhile sizeable population surveys in the United States show that 
psychotherapy has assumed a less prominent role in mental health care20. For example, from 
1996 to 2006, among antidepressant users the percentage of people who underwent 
psychotherapy declined from 31.50% to 19.87%18. In low-income and middle-income 
countries, psychological treatments are hardly available with notable exceptions21 (see also 
Section 2, Worldwide).  
At the same time, however, there are indications that the majority of patients prefer 
psychotherapy over medication: a meta-analysis of patients with a range of mental disorders 
(including depression, anxiety, insomnia, bipolar disorder, schizophrenia, substance-related 
disorder, eating disorder, and personality disorder) estimated that approximately 75% of 
patients prefer psychotherapy as their treatment4. Such a preference underscores the importance 
of progressing psychological treatments research. Meanwhile, clearly some patients prefer 
pharmacological treatment, and some may in fact have no preference. We do not seek to 
reinforce what we believe to be a misplaced dichotomy between biological and psychological 
approaches (see Section 3, on Combination Treatments). Rather, we seek a research agenda that 
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is open to multiple perspectives, does not neglect one at the expense of another, considers links, 
is informed by patient preferences, and ultimately leads to the greatest clinical impact.  
 Although as mentioned above the majority of patients prefer psychotherapies above 
medications, the availability of such treatments is a major problem in many if not most 
countries5, because of financial constraints, or because there are not enough trained 
psychotherapists to deliver the evidence-based treatments. This means that psychotherapies are 
often mostly delivered in high-income countries, to those who can afford it and know the ways 
to find therapists. Several alternatives are being developed to increase access to psychological 
services, such as the Increasing Access to Psychological Treatment (IAPT) program in the UK, 
where low-intensity psychotherapies are made available on a large scale and high-intensity 
therapies are available for those who do not respond to low-intensity therapies. Internet-
interventions (see Section 5) can be an important help in making psychotherapies better 
available to those who need it because they can be offered relatively inexpensively, cheaply and 
with a low threshold for access. Another important development to make therapies better 
accessible is to use lay-health counsellors. This has been done in other fields of health care as 
well, and in several Low and Middle Income countries experiments have shown that these 
counsellors can deliver therapies in an effective way, at low cost (see Section 2, Worldwide). 
 
Seeing further: Psychological Treatment Research in Tomorrow’s Science 
 
 
What needs to be achieved? In a nutshell - improved psychological treatments to help 
reduce the burden of mental disease worldwide. Psychological treatments are clearly just one of 
many necessary routes to improve global mental health yet have an important part to play. The 
psychological treatment research landscape is ripe for invigoration – it offers truly exciting and 
opportune areas for mental health sciences. Indeed, the enormous need for improved treatments 
provides a rich vein for scientific enquiry across disciplines. Recruiting insights from multiple 
areas of science may allow us to ‘stand on the shoulders’ of existing evidence-based 
“Improved psychological treatments 
to help reduce the burden of mental 
disease worldwide.” 
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psychological treatments and ‘see further’ footnote #2 in order to improve psychological 
interventions. It might also be the case that recruiting insights from psychological treatments 
will allow us to stand on the shoulders of existing scientific evidence and “see further” to 
improve scientific theory. Greater collaborative endeavours between clinical and basic 
researchers of all stripes will help in this regard2. 
Here we discuss opportunities to focus future research efforts to improve mental health. 
Ripe areas of enquiry include (1) understanding the mechanisms underlying psychological 
treatments; (2) increasing their worldwide access; (3) developing cross-modal treatment 
approaches; and (4) enhancing a preventative focus and developmental approach. To do this we 
need to harness tools provided by (5) new technologies; (6) improved trials methodology; and 
(7) improved training in interdisciplinary mental health sciences. The targets of psychological 
treatments should embrace challenging areas, such as (8) the inherent complexities of mental 
health disorders and of (9) suicide prevention. The array of challenges ahead to which a 
psychological perspective can contribute will require fresh innovation (10). 
However, the idea of “seeing further” requires ideas to be taken, tested, rejected, or 
developed and so forth in line with scientific method and the mental health challenges of the 
time. That is, we need ideas and evidence to be rigorously examined, explored, and then kept, 
refined or discarded as appropriate in line with evolving research findings (rather than for 
example therapeutic habit and allegiance to a way of clinical training, or science focused 
inwardly on science rather than its genuine application). This means in essence that we need 
change – change that is not only driven by scientific knowledge but by pressing mental health 
issues as they arise. 
We therefore make an analogy with a British contemporary art initiative – which 
engages with London’s Trafalgar Square’s empty plinth. There are statues on three of four of 
the plinths in the corners of Trafalgar Square. The fourth plinth stood empty for over a century.  
Now, the so called “Fourth Plinth Programme”22 invites world class artists to make 
‘astonishing’ new works for the centre of the capital city. Commissions create a rolling 
programme of temporary artworks rather than settling permanently on one figure or idea. These 
                                                          
footnote #2 “If I have seen further it is by standing on ye shoulders of Giants”; Letter from Isaac 
Newton to Robert Hook dated 5th February 1676, as transcribed in The Correspondence of Isaac 
Newton. (1959). H. W. Turnbull, Ed.  (Vol. 1.) Cambridge: Cambridge University Press. 
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resultant sculptures tend to be shown for a year, sometimes only months – sometimes there are 
gaps. But the momentum and scrutiny continues. Associated initiatives encourage projects and 
creative thinking around past and present artworks displayed on the Fourth Plinth. Meanwhile, 
the best use of the fourth plinth remains the subject of debate and discussion in the public, 
media and art world.  
Bringing this metaphor back to psychological treatments research - innovation, rotation 
of ideas and the encouragement of robust critical debate needs to be a clear part of the way 
forward. As mentioned above, ideas can be taken, tested, rejected, or developed and so forth in 
line with scientific method and the mental health challenges of the time. That is, the objects of 
enquiry change, but the principles of seeking to improve our research efforts towards improved 
mental health persist. Rather than being prescriptive regarding the future of psychological 
treatments research, this article sets out various suggestions and principles to guide the research 
that should  apply across different mental disorders / transdiagnostic processes, approaches, 
countries and, indeed, to the new and future generations of mental health researchers. These 
principles should change with scrutiny over time, as new principles are developed, scrutinised, 
and refined to reach the need and scale of mental health problems worldwide. How best to 
strengthen psychological treatments should be subject of research, debate and discussion 
involving both the psychological treatments and mental health science fields, and many of those 
beyond. 
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Figure. The Forth Plinth, Trafalgar Square London (photo by E. Holmes, 2016) 
When considering the traditional delivery method of psychological treatments, it is 
fascinating that two humans talking with each other for a matter of hours during therapy 
sessions can bring about changes that remediate years of suffering mental distress. While 
clearly the presence of another human can be helpful, that alone is unlikely to provide the key 
to psychological treatment success. Evidence-based psychological treatments involve far more 
than only skills which boost therapeutic alliance. We now know therapeutic effects can be 
achieved without a therapist being physically present (e.g., via Internet therapy) and that some 
psychological techniques can be effective when delivered by lay workers with modest training. 
Moreover, neuroscience continues to reveal how efficiently the mind can work under certain 
parameters (e.g., in modulating memory) by a range of techniques which may or may not 
require another human to be present. The emotional, behavioural and social changes rendered 
through therapy open fascinating mechanistic questions for science e.g., why do effective 
psychological treatments work? The identification of specific targets for mechanistic questions 
might be facilitated by not only by quantitative scientific methods but by qualitative methods 
used in humanities and social sciences, such as detailed narratives of individuals’ experiences 
as they undergo psychological treatments. Once potential targets are identified in this way, they 
could be subjected to experimental investigation to establish causality for therapeutic change.  
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We turn now to focus and elaborate on ten key themes that we see as instrumental to 
consider in developing an agenda to progress the science of mental health treatment research. 
These themes are not exhaustive and many more are to be welcomed for future scrutiny.  
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1. Why do existing treatments work? Making the case for mechanisms of psychological 
treatments 
 
 
 
Overview: Mechanisms 
It is now known that certain psychological treatments are effective but we know little 
about the processes through which therapeutic change occurs. Knowledge of mechanisms is 
essential to deriving and honing treatment strategies to more directly target agents of change, 
trim away irrelevant strategies, and develop novel approaches that are even more expeditious 
and effective.  Knowledge of mechanisms also permits greater precision in matching 
psychological treatments to the needs of each individual in order to improve outcomes.   
Mechanisms research presents exciting directions for the future of psychological 
treatment research. However, the current state of play and wealth of neuroscientific studies in 
the area of psychopathology have generally taken the approach of simply describing differences 
between groups of individuals with and without a diagnosis – an approach which cannot 
unambiguously identify causal mechanisms. Thus, to move the field toward causality, we should 
seek to maximize research on mechanisms by firmly framing it within a clinical treatment 
context to: a) understand how existing treatments work; b) improve these treatments; and c) 
derive new treatments. Greater collaborative endeavours between clinical and basic 
researchers will help in this regard.  
 
What is a mechanism of psychological treatment? 
 Mechanisms are “the steps or processes through which therapy (or some independent 
variable) actually unfolds and produces the change. Mechanisms explain how the intervention 
“Although there are many EBTs (evidence based therapies) available, there 
is little understanding of the mechanisms of change (i.e., precisely how they 
work; Kazdin, 2007). Understanding mechanisms of action may be extremely 
important…” 
 
Kazdin, A. E. (2007). Mediators and mechanisms of change in psychotherapy 
research. Annual Review of Clinical Psychology, 3, 1-27. 
work; Kazdin, 2007)23. Understanding mechanisms f action may be 
extremely important…” 
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translates into events that lead to the outcome or precisely what was altered that led to symptom 
change”23. A mechanism is an explanatory construct and not simply an intervening variable that 
explains the statistical relation between an intervention and an outcome - i.e., a mediator. For 
example, the finding that changes in perceived self-efficacy and outcome expectancy 
statistically mediate subsequent changes in anxiety and functioning24 does not explain how 
changes in self efficacy and outcome expectancy lead to those outcomes. The underlying 
changes responsible for symptom improvement could involve multiple processes, including (but 
not limited to) neural systems, other physiological systems, cognitions, emotions and behaviors, 
see Panel 1. 
 
Panel 1. What is a Mechanism of Psychological Treatment? 
 Processes through which treatment leads to symptom change 
 An explanatory construct – not simply an intervening variables that explains the 
statistical relationship between an intervention and outcome (i.e., mediator) 
 Processes include (but are not limited to) neural systems, other physiological systems, 
cognitions, and behaviors  
 
 The processes through which psychological treatments produce change often overlap 
with, or are complementary to, mechanisms that are responsible for the onset and/or particularly 
the maintenance of psychopathology (hereafter referred to as mechanisms of psychopathology). 
The NIMH Research Domain Criteria (RDoC) Initiative has made strides in directing the search 
for mechanisms of psychopathology away from the constraints of categorical diagnostic criteria 
and towards dimensions of observable behavior and neurobiological measures (NIMH Strategic 
Plan, http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml). The RDoC 
initiative aims to “elaborate a set of psychological constructs linked to behavioral dimensions 
for which strong evidence exists for circuits to implement these functions, and relate the 
extremes of functioning along these dimensions to specified symptoms (i.e., impairment)”25.  In 
essence, the RDoC framework aims to identify biopsychological explanations or “process 
constructs” for clinical phenomena; these same “process constructs” could explain change in 
clinical phenomena throughout treatment. The provisional list of RDoC explanatory constructs 
includes Negative Valence Systems, Positive Valence Systems, Cognitive Systems, Systems for 
Social Processes, and Arousal/Modulatory Systems, with each construct comprised of more 
specific subconstructs25. The constructs are assessed with measures that represent at least seven 
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levels (called ‘units of analysis’), including genes, molecules, cells, circuits, physiology, 
behavior, and self-reports. Identifying a mechanism using one unit of analysis does not exclude 
mechanisms identified using other units of analysis. The RDoC matrix also includes paradigms 
for assessing units of analysis (as shown in Table 1 below). 
 
Table 1: NIMH Research Domain Criteria Matrix. 
 
  
Mechanisms of psychopathology vary from being predominantly distal (e.g., effects of 
early life adversity which may have occurred many years previously upon inflammatory 
markers for depression26) to predominantly proximal (e.g., ongoing biases in autobiographical 
memory for depression27) (see28 for a recent discussion of these ideas). They also vary from 
being predominantly fixed (e.g., genes, albeit with variations in expression) to predominantly 
malleable (e.g., negative interpretation bias for ambiguous stimuli).  Psychological treatments 
generally target predominantly proximal and malleable mechanisms of psychopathology, as is 
the intended effect of attention bias modification training for anxious individuals who exhibit 
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selective bias of attention towards threat-relevant stimuli29.  Alternatively, psychological 
treatments may target factors that differ from but compensate for mechanisms of 
psychopathology, as is the intended effect of compensatory cognitive training for psychosis30. 
Even though less commonly targeted, distal mechanisms may be particularly important targets 
of prevention efforts. Notably, not all treatment mechanisms are directly tied to mechanisms 
responsible for the onset or maintenance of psychopathology; in some cases, treatments work 
through independent processes, as is the case for applied behavioral analysis techniques for 
treating autism31. 
 
What is the state of the field? 
 
A number of pivotal evidence-based psychological treatments have evolved by 
specifically targeting identified mechanisms of psychopathology. One example is the 
treatment of panic disorder. Through a series of experimental investigations and prior animal 
modelling, interoceptive conditioning (i.e., acquired fear of visceral or other internally 
generated stimuli due to pairing with an aversive outcome, as in the case of pairing elevated 
heart rate with the possibility of heart attack) and catastrophic misappraisal (i.e., 
misinterpretations of interoceptive stimuli as harmful or threatening) were recognized as 
mechanisms underlying the fear of bodily sensations that characterizes panic disorder32-34. 
Psychological treatments were developed to target those mechanisms precisely in the form 
of interoceptive exposure35 (i.e., repeated exposure to interoceptive stimuli in the absence of 
aversive outcomes) and cognitive restructuring36 (i.e., reasoning skills to replace catastrophic 
interpretations with evidence-based interpretations). This type of treatment has been shown 
to be particularly effective for panic disorder, and more effective than nontargeted 
supportive psychotherapy (Hedges g = .35, CI 95% .04-.65)37. Similarly, the 
conceptualization of instrumental reinforcement of compulsions led to a treatment known as 
exposure and response prevention for obsessive compulsive disorder38. In this 
conceptualization, the distress-reducing effects of compulsive washing in response to 
obsessive thoughts of being contaminated reinforces and therefore increases compulsive 
washing with each subsequent obsessive thought; the treatment combines exposure to 
reminders of the obsessive thoughts (such as a dirty piece of clothing) or the thought itself 
(such as the thought of being covered in germs) with prevention of washing. This treatment 
approach is very effective for obsessive compulsive disorder, and more so than nontargeted 
psychological control conditions such as relaxation training (Hedges g = 1.29, CI 95%  
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0.76–1.81)39. Another example is behavioural activation therapy which targets deficits in 
positive reinforcement as a contributing factor for depression40. This approach aims to 
increase access to positively rewarding stimuli, and more recently, achieve actions that are 
value-driven and overcome task-related avoidance41. Behavioural activation for depression is 
highly effective relative to comparison control interventions, including waitlist and 
nontargeted psychological control conditions (Hedges g = 0.87, CI 95% 0.60 ~ 1.15)42 . 
Overall, this mechanistic approach informed the development of psychological treatments 
that are more precise, efficient, and effective than treatments that do not target specific 
mechanisms. That said, the strongest effect sizes derive from comparisons with no-treatment 
or wait-list control conditions, with the latter potentially inflating effect sizes43, and some of 
the meta-analytic findings presented above included wait-list control conditions (e.g.,42). 
That comparisons to usual-care typically yield lower effect sizes than comparisons to no-
treatment or wait-list controls44 may speak to the importance of common factors (such as 
goal consensus, therapeutic alliance, empathy, expectations and therapist effects) that are 
relevant to all psychotherapies45. Notably, common factors do not obviate the importance of 
mechanistic research but rather imply the value of taking common factors into account when 
evaluating mechanisms of specifically targeted therapeutic approaches.  
However, despite purported treatment mechanisms, including the ones described for 
panic disorder, obsessive compulsive disorder, and depression, we have little evidence for 
the precise mechanisms through which psychological treatments actually work. Although 
recent developments in neuroscience have ignited more interest, as described below, the 
majority of studies to date have not evaluated mechanisms of treatment. Even the study of 
mediation is limited and often plagued by lack of sufficiently rigorous methodology needed 
to claim that a particular variable statistically predicts subsequent change in outcomes
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. For 
example, while there is good evidence for the efficacy of interoceptive exposure and 
cognitive restructuring for panic disorder, and while extinction of fear of interoceptive cues 
and reduction in catastrophic appraisals occur as a result of treatment, we have little direct 
evidence that the treatments work through extinction of conditional fear of interoceptive cues 
or reduction of catastrophic appraisals – a claim that would require that changes in the 
purported mechanisms explain subsequent changes in symptoms (as described in a later 
section). Similarly, while behavioural activation for depression may lead to changes in 
reward processing, there is no evidence that the treatment works through changing neural and 
behavioural sensitivity to reward. 
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To make matters worse, the focus of psychological research has slowly shifted 
away from a mechanistically informed approach. Instead, the focus has shifted towards 
‘modifying or adapting’ existing manualized psychological treatments, sometimes 
superficially, for different populations and settings. This approach of modification most 
commonly applies to cognitive and behavioral therapies. Although valuable for the 
advancement of treatment implementation in different settings, this has resulted in a 
regrettable divorce from the foundations of mechanistically informed psychological 
treatments that in turn has thwarted investigation of their mechanisms of action. 
Why it is important to understand mechanisms of psychological treatments? 
Without knowledge of mechanisms, pathways to intervention development and 
refinement remain limited. With knowledge of how change occurs, therapeutic strategies that 
more directly, precisely and effectively produce such change can be developed46. Also, those 
therapeutic strategies that do not have an impact upon the critical processes can be removed, 
making treatments more efficient as well as more effective46. Moreover, by disconfirming a 
purported mechanism, research attention can be redirected toward investigating alternative 
mechanisms and to the development of novel treatments that most effectively and efficiently 
target them, see Panel 2. 
 
 
Panel 2. Reasons for Understanding Mechanisms of Psychological Treatments 
 Hone treatments to more directly and efficiently target processes responsible for 
change 
 Uncover essential moderators of treatments outcome and improve precision in 
treatment matching 
 Develop training programs for prevention of and recovery from psychopathology 
 Limit wasteful and inefficient treatments 
 Provide evidence for specificity above and beyond nonspecific factors responsible 
for the “dodo bird” effect 
 
Psychological treatment mechanisms may uncover essential moderators of treatment 
outcome, and thereby lead to greater precision in matching treatments to individual needs44. 
A few recent examples are provided below. Conclusive findings will depend upon replication 
with significantly larger sample sizes than those in the extant literature; these examples 
27  
simply provide illustrations of ways in which the field could consider moving forward. For 
example, initial interest in attention bias modification training for anxious individuals waned 
as a result of mixed findings and limited effect sizes47. More recent research has provided 
some indication that the effects of attention bias modification training are superior for 
individuals with stronger levels of attentional bias at baseline29 and for those with low 
expressing forms of the serotonin transporter gene (5-HTTLPR)48. As another example, it has 
been suggested that extinction-based exposure therapy to trauma cues for posttraumatic stress 
disorder may function in part by enhancing prefrontal cortex (PFC) inhibitory regulation over 
amygdala responding49. Neuroscientists have identified subtypes of individuals with 
posttraumatic stress disorder, with the majority showing amygdala hyperactivation and PFC 
hypoactivation to trauma reminders and a minority (~30%) showing the reverse pattern of 
amygdala hypoactivation and PFC hyperactivation50. If it can indeed be established that 
exposure therapy works at least partially through enhancing PFC regulation of the amygdala, 
then exposure therapy may be more effective for the former set of individuals with 
posttraumatic stress disorder compared to the latter. 
Not only is identification of such “mechanistic” moderators valuable for precision in 
treatment matching, but uncovering such moderators in turn improves the elucidation of 
psychological treatment mechanisms46. To follow the prior example, by collapsing across the 
entire sample with posttraumatic stress disorder (those showing amygdala hyperactivation as 
well as those showing amygdala hypoactivation) the extent to which change in amygdala 
activation serve as a treatment mechanism is likely to be nullified. By recognizing individual 
baseline differences, differential mediational pathways could be uncovered for different 
individuals (such as the possibility of amygdala deactivation for those who initially present 
with hyperactivation and vice versa for those who initially present with amygdala 
hypoactivation). Again, these are simply illustrative examples, but a mechanistic approach to 
moderation avoids the trial-and-error default position of assuming that a given psychological 
intervention strategy works through the same mechanisms for everyone. Another speculation 
is that behavioral activation for depression41 (which involves scheduling activities that are 
rewarding) leads to symptom improvement through enhancing approach motivation or initial 
responsiveness to reward within ‘Positive Valence Systems’ for some individuals, while for 
other individuals it may reduce threat or potential threat within ‘Negative Valence systems’ 
or even modulate ‘Arousal Systems’ through regulating sleep-wake cycles. 
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Additionally, psychological treatments with a mechanistic focus can be turned into 
training in every day habits that pertain to prevention of and recovery from mental health. 
Examples of such attempts include training in mindfulness techniques to reduce affective 
memory bias and reduce development of, or relapse into, depressive ruminative states51. 
Other examples include the delivery of cognitive behavioural therapy (CBT) as an adjunct to 
usual primary care for individuals who are depressed and have not responded well to 
medication alone52. In one study, short-term focused CBT was associated with significantly 
lower scores on depression three to five years later relative to usual care alone52. Similarly, 
cognitive therapy decreased recurrence of depression relative to treatment as usual over a ten-
year interval in remitted patients with histories of recurrent depression53. Together, these data 
suggest that CBT/CT provided skills that were embedded into everyday lives and led to 
sustained improvements in the long term. 
 Failure to address mechanisms of psychological treatments bears certain costs. For 
example, the development of novel and more effective treatments could be stymied by 
continued focus of attention upon modifying procedural elements to existing treatments 
without fully understanding the processes that lead to change. We encourage the 
development of a larger evidence-base for critical processes for therapeutic change, and 
specifically which psychological treatments (existing and newly developed) “hit” which 
process/es. This evidence-base can and should include both common factors as well as specific 
factors of psychotherapies25. That is, it will be informative to know which psychological 
treatments exert their effects primarily through common, nonspecific factors versus more 
targeted, specific factors, and whether the common and specific factors are of greater relevance 
for one mental health problem or individual over another. Moreover, such an evidence-base 
offers the potential to move the field forward beyond the longstanding debate between (a) all 
psychological treatments are equally effective (i.e., “dodo-bird hypothesis”)54  and (b) 
differential treatment effects55. That is, we have the opportunity to evaluate whether matching 
mechanistically focused treatments to individual profiles of underlying dysregulation leads to 
superior outcomes relative to nonspecific factors that are common across psychological 
treatments. Of course, applying mechanistically focused personalization and understanding the 
role of common factors are not the only pathways by which we can improve psychotherapy 
outcomes; other factors that warrant consideration include the personal resources and social 
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context of those in need, as well as the service delivery systems in which treatments are 
delivered.  
 
Panel 3. Recommendations for Identifying Potential Mechanisms of Psychological 
Treatments 
 Develop a model of explanatory specificity 
 Experimental investigation of an explanatory construct to establish causal validity 
o Human studies to demonstrate that manipulation of purported construct 
leads to symptom change (experimental psychopathology) 
o Animal studies to allow more precision and elucidation of targets that 
cannot be studied in humans 
o Reverse-translation models utilizing clinical research to inform models to be 
tested in animals 
 Iterative reciprocal information flow between experimental psychopathology 
studies in humans and animals 
 
As reviewed by Kazdin23, mechanisms involve a deep level of explanatory specificity 
and hence are theory-driven. They are elaborated through plausible and coherent reasoning 
based on integration with broader scientific knowledge, and at the same time possess 
specificity in the explanation provided for how change in the mechanism in turn accounts for 
change in outcomes
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. Once theoretical mechanisms are elaborated, they are subjected to 
experimental investigations that validate their causal influences upon selected outcomes. This 
endeavour is represented in the field of “experimental psychopathology” (see Panel 3). 
Demonstration that experimental manipulation of a purported mechanism leads to 
symptom change is a powerful method for validation. Experimental studies of this kind in 
human samples can identify key processes that maintain or change aspects of 
psychopathology. These studies also elucidate which of the processes underlying 
psychopathology can (versus cannot) be modified, and therefore are appropriate treatment 
targets. A recent burgeoning of interest in the mechanisms that underlie psychopathology 
has been fuelled largely by advances in cognitive science and neuroscience46. As one 
example, increased activation in affective brain networks and decreased activation in 
cognitive control and social cognitive networks as youths listen to criticism from their 
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mothers has been identified as a potentially critical mechanism in emotional development56. 
These findings could inform treatments aimed at increasing effective parenting to reduce 
the risk of mental health disorders in offspring. 
The direct application of identified mechanisms of psychopathology to mechanisms 
of psychological treatment is well-represented in fear learning and exposure therapies for 
anxiety disorders. For example, pharmacological agents that facilitate the consolidation of 
fear extinction learning (e.g., d-cycloserine) have been shown to have beneficial effects in the 
context of exposure therapy57 (although there are some mixed effects, possibly due to 
mechanistic moderators58). Another example derives from the evidence that retrieving 
already stored memories induces a process of reconsolidation59. Once retrieved, the memory 
has to be rewritten into long-term memory, which requires neurochemical processes (de novo 
protein synthesis) in the brain. This process give rise to the fascinating possibility of 
changing memories post factum, during the reconsolidation time window upon retrieval. 
Pharmacological (i.e., propranolol) agents and behavioural techniques (i.e., extinction) have 
been shown to interrupt the reconsolidation process in humans, albeit with some mixed 
results60, limiting boundary conditions and conceptual challenges61,62. Most recently, 
engaging in a highly visually- absorbing computer game (‘Tetris’) after a memory-reminder 
cue was found to interrupt reconsolidation of intrusive visual memories induced by 
experimental trauma63. 
In other areas, demonstrations of disturbances in autobiographical memory as 
potential mechanisms of depression have led to novel therapeutic strategies such as memory 
specificity training or positive memory elaboration for depression27. More mechanistic 
research is needed in general and particularly in youth samples, where there is great need for 
innovative psychological treatments that precisely target narrowly specified mechanisms 
consistent with developmental models of aetiology (see also Section 4, When in life). 
Purported mechanisms can be tested in animals with a much more precise level of 
measurement and causality than is possible in human beings. Furthermore, animal studies are 
invaluable for identifying basic processes and mechanisms that are not possible to address in 
humans due to practical or ethical constraints. Indeed, the clinical applications of d-
cycloserine for exposure therapy and the disruption of reconsolidation for fear memories first 
derived from careful experimentation in animals59,64. Animal studies have also elucidated the 
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potential value of disruption of reconsolidation in the treatment of substance 
abuse/dependence65. Ongoing animal work is currently examining pharmacological agents 
that regulate the stress response via inhibition of the renin-angiotensin system (i.e., losartan) 
as another method for enhancing consolidation of extinction66. Advances in understanding 
the neurobiology of rodent self-grooming may identify potential treatment mechanisms for 
repetitive behaviours such as compulsions67.  
In reverse-translation approaches, clinical research informs models to be tested in 
animals. For example, paradigms for assessing depressive cognitive styles such as pessimism 
that have been validated in human samples have now been reverse-translated to paradigms 
that measure judgment bias in rodents68. Similarly, drawing from human work on reward 
systems, paradigms have been developed to assess decision making between cues that predict 
reward versus cues that predict punishers in rodents; decision making was shown to be 
influenced by negative state induction (via unpredictable housing treatment)69. 
Iterative reciprocal information flow is needed between experimental studies in 
humans and animals. While there are some examples of such reciprocity, as in the cases of d- 
cycloserine and memory reconsolidation, for the most part a huge gap exists between basic 
and clinical researchers. This gap hinders the development of more refined animal models of 
psychopathology and treatment and their translation to clinical samples. The reverse and 
forward translation of advances in basic science and clinical science is essential. 
 
 
Panel 4. Recommendations for Evaluation of Mechanisms of Psychological 
Treatments 
 Evaluate within the context of properly powered clinical trials 
 Develop measures (i.e., of mediators) that are reliable, valid and sensitive to 
change and represent multiple modalities (genes, molecules, cells, circuits, 
physiology, behavior, cognition, self-report) 
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 Establish mediation by showing change in mediator over treatment and that change 
in the mediator precedes and predicts clinical outcome 
o Temporal precedence (change in mediator precedes and predicts 
subsequent change in symptoms); value of repeated measurement 
o Specificity of mediation to a single or limited number of mediators 
o Specificity of mediation to a theoretically-relevant mediator versus non- 
relevant mediator for a given treatment, or of a theoretically relevant 
mediator to one treatment relative to another treatment to which it does 
not have theoretically relevance 
o Dose response relationship between degree of change in mediator and 
degree of clinical improvement 
o Consistency in independent replication 
 Evaluate mediation for elements or specific therapeutic strategies rather than 
packages of treatment elements 
 
Once a mechanism has been identified through careful experimental demonstration, 
for example via a series of experimental psychopathology studies, then it can be evaluated 
within the context of properly powered clinical trials, involving more extensive 
collaborations than currently exist. This requires measures of the purported mechanisms that 
are reliable, valid, and sensitive to change, as these measures will become the mediators that 
are evaluated statistically. A major contribution to this effort will be funding to establish a 
list of candidate mechanisms that explain therapeutic change (based on demonstrations that 
their experimental manipulation influences selected outcomes in animal or human studies) 
and a list of measures for each candidate mechanism. Here, the RDoC notion of units of 
analysis provides a helpful framework for choosing measures from multiple modalities. 
Kazdin
23 has carefully outlined the steps necessary in order to establish that a 
measure is a mediator of a psychological treatment. As an initial step, a strong association 
must be demonstrated between the psychological treatment and the hypothesized mediator 
(i.e., the mediator changes over the course of treatment), and between the mediator and 
therapeutic outcome (i.e., change in the mediator is related to clinical outcomes). 
Kazdin23lists a number of methods that allow greater attribution of causality to the mediator 
(underlying mechanism). One method is temporal precedence, since mediation cannot be 
presumed unless changes in the purported mediators (underlying mechanisms) occur prior to 
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and then predict changes in outcomes. Temporal precedence necessitates repeated 
measurement of mediators (underlying mechanisms) and of outcome variables throughout 
treatment, ideally in every treatment session. 
Greater attribution of causality also derives from evidence for specificity of the 
linkages; the finding that multiple mediators (underlying mechanisms) explain an outcome is 
much less convincing than identifying a single, targeted mediator. Even more convincing is 
when the purported mediator (underlying mechanism) of a particular psychological treatment 
predicts outcomes relative to an alternative mediator of a different mechanism that is not 
theoretically tied to the treatment. Moreover, stronger mediation by a purported mediator for 
a treatment to which it is theoretically tied relative to a treatment to which it is not 
theoretically relevant is another avenue for demonstrating specificity. Evidence for a dose 
response relationship, in which stronger doses of the proposed mediator are associated with 
greater changes in symptoms, also strengthens the argument for causal linkage. The 
consistency with which the relations are observed, across independent replications, is another 
validator. Of course, the demonstration of these criteria will require large samples, much 
larger than those that neuroscientists and clinical scientists typically study. Hence, a 
mechanistic approach will necessitate collaborative, multi-site studies. 
Among the challenges for research on mechanisms are sample size and the need for 
interdisciplinary research, although we also note that for certain mechanistic questions 
appropriately powered experimental studies of small samples are also informative. Research 
on mechanisms is more complicated than examining whether therapies work or not, because 
causality of the mechanisms are not established easily, and furthermore, doing so requires 
several types of research from different domains. Given that mechanisms have not been 
established in the past decades of psychotherapy research, in order to make progress the way 
forwards will require a strong investment from funders and collaboration among researchers, 
focusing on common goals. 
Finally, the field would be advanced by a listing of the various therapeutic elements 
that comprise psychological therapies, as has already been initiated70. As it currently stands, 
psychological treatments are mostly packages of different elements, such as cognitive 
restructuring, self-monitoring, problem solving, relaxation training, assertiveness training, 
and so on. The more elements that are combined in a psychological treatment, the harder it is 
to establish mechanistic specificity. Greater precision is likely from evaluating the
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mechanisms of particular procedural elements rather than combinations of elements71 
(see Panel 4). The fact that the task ahead is difficult is underscored by the absence of large 
scale, major progress since Kazdin’s original call for better methods for establishing 
mediation and mechanistic approaches. However, as noted, greater collaboration across 
clinical researchers and basic scientists combined with new methods and technologies 
position us to make more headway than ever before.  
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2. Where can psychological treatments be deployed? Research to improve mental 
health worldwide 
 
Overview: Where - mental health worldwide 
Low or no access to efficacious psychological treatments is not only a major problem for the 
majority of people in low- and middle income (LAMIC) countries, but is also problematic for 
a significant portion of people in high-income countries. In the future brief, flexible, modular 
and efficacious treatments derived from mechanistic research could enable us to more 
efficiently adapt such treatments to different cultural contexts. Furthermore, they could help 
us train lay persons with no previous experience of providing services within mental health to 
help implement such interventions within a frame of low-intensity treatment using modern 
techniques on a broad basis both in LAMI and high-income countries. Further research is 
needed on 1) how to derive such treatments and adapt them to the local needs, priorities, 
traditions, and cultural norms for different environment, 2) education and training for lay 
persons to acquire proficiency to deliver such treatments as lay counsellors in a sustainable 
way, and 3) models of delivery of mental health with long-term sustainability.  
 
What is the impact of mental health disorders internationally?  
As discussed, mental disorders constitute a significant part of the overall burden of 
disease worldwide8,72,73. Together with substance use disorders, mental disorders account for 
183.9 million disability-adjusted life years (DALYs) or 7.4% of all DALYs worldwide8. The 
costs of untreated mental health problems are huge5,8, not only in terms of monetary cost for 
society, but also in terms of decreased quality of life of individuals and lost opportunities. 
Mental health problems also interact with other serious conditions such as cardiovascular 
diseases, ischemic stroke, and HIV, increasing the risk of premature death74-77. 
Psychological treatments from an international perspective 
There are a significant number of efficacious psychological treatments for a wide 
range of mental disorders, which have mainly been developed in North America or Europe, 
and are typically designed for delivery through one-to-one psychotherapy by highly trained 
professionals. However, the majority of those in need around the globe do not have access to 
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such treatments. According to the WHO, at a global level, 90% of individuals with mental 
health problems do not receive treatment78. The majority of the world lives in developing 
countries, and yet most of health care resources are situated in developed countries. Despite 
this fact, low or no access to efficacious psychological treatments is not only a major 
problem for the vast majority of people in low- and middle-income countries 
(LAMICs)79, but is also problematic for a significant portion of people in high-income 
countries80. As argued by Kazdin and Blase5, we will have only limited success in decreasing 
the prevalence and incidence of mental illness without a major shift and expansion in clinical 
practice and intervention research. 
Panel 5. What Increases Access to Psychological Treatments Worldwide? 
 Existence of low cost, simple, specific and effective treatments: such treatments can 
more easily be implemented regardless of context  
 Task shifting: educating people without prior experience of work within mental 
health services to deliver psychological interventions 
 Low intensity intervention: self-help interventions comprising the most potent 
components of effective psychological treatments that can be provided through 
books, CD/DVD, Internet or other media combined with brief, usually remote, 
support (e-mail or phone) during a few weeks 
 Cultural adaptation: rooting the treatment in sociocultural context (traditions, 
expectations, norms, symbols, etc.) to make sure that it is perceived as intended 
 
Lack of skilled human resources (i.e., therapists) and low acceptability of 
psychological treatments across cultures have been suggested as the two major barriers for 
increasing access to evidence-based psychological treatments in LAMICs81. WHO estimated 
a shortage of 1.18 million mental health workers for 144 LAMICs82. Other significant 
barriers include prevailing public-health priority agendas and inadequate investment in 
mental health care, stigma associated with accessing mental health care, and challenges in 
using primary-care settings for implementation of mental health care83, see Panel 5. 
Research to improve worldwide access to psychological treatments 
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Global access to psychological treatments could become a reality given adequate 
global and local political decisions and a research agenda including (and not limited to) the 
following conditions, see also Panel 6. 
We need to derive psychological treatments that are brief, flexible, modular 
and efficacious, streamlined to remove any and all complexities unnecessary for 
treatment gains. These are the characteristics that would be advantageous for the successful 
scale-up of psychological treatments. Such treatments will be aided by research into 
mechanisms of action in psychological treatments (see Section 1 above, on Mechanisms), and 
a consideration of the core psychopathology of, and across, mental disorders. Large and 
complicated psychological treatment packages can only be delivered by highly trained 
professionals to a minority of people who can afford the high costs associated with such 
treatments. On the other hand, simplified, clearly defined treatments may be more readily 
adapted to local needs and delivered by lay mental health workers on a larger scale, and 
delivered as low-intensity treatments e.g., via the Internet. Mechanistically-informed 
treatments could also afford flexibility, for example in shaping the treatment in line with local 
cultural norms and conditions. 
Instead of adapting “top down” a treatment package developed in another cultural 
context, mechanistically-driven psychological treatment innovation offers a profitable 
research direction. For example, if one of the major maintaining factors in depression 
concerns lack of positive reinforcement in daily life (c.f. Section 1, Mechanisms, Positive 
Valence Systems), then treatment strategies to increase positive reinforcement can be 
formed in many different ways depending on what is the most relevant, acceptable, and 
affordable in the specific context or culture in which the problem exists e.g. via various 
cognitive, behavioural or psychosocial techniques. Such treatments could each have flexible 
forms, but be functionally identical. 
Psychological treatment development for example in LAMICs has typically 
focussed on the important issues of availability and access, and researchers have taken a 
pragmatic approach to treatment development itself. Yet future research might also seek to 
harness scientifically driven developments. Moreover, the utility of building psychological 
treatments on the basis of sound psychological theories and empirical knowledge gained from 
research on the processes of action in treatment may afford particular strengths: by opening 
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opportunities for cultural adaptation and psychological treatment across international 
contexts. As another example, research that has tested theories about the mechanisms of 
action in exposure therapy for anxiety disorders84-88 has provided invaluable knowledge, 
leading to the enhanced flexibility of exposure therapy, which in turn could be tailored for 
global adaptation. It is the hope that research on basic mechanisms will indicate potential for 
brief, flexible, and highly efficacious psychological treatments89-92. Future research needs to 
move such work into intervention formats that are acceptable and efficacious cross-culturally, 
and are deliverable on a wider scale.   
We need to rethink the traditional models of one-to-one delivery of psychological 
treatments by skilled psychotherapists who have had many years of training, and consider 
more efficient ways of treatment delivery5,93. Given the limited human resources in terms of 
highly trained and skilled professionals internationally, a shift towards collaborative models 
of care delivery has been proposed in which novel strategies such as task shifting (e.g., 
educating people with no prior experience of work within mental health services to become 
lay counsellors) has been successfully used to deliver streamlined treatment of psychological 
disorders with promising results81,94-96. Nevertheless, empirical questions remain: how best 
can we train people to become lay counsellors in a sustainable way, and what barriers might 
there be for such sustainability? The delivery of therapy in group rather than one-to-one has 
clear benefits for delivery efficiency. 
Other research questions include how many training, supervision, and booster 
sessions will be needed to ensure high quality delivery of treatments? As summarised by 
Dawson and colleagues97, the majority of studies in which potential treatment group leaders 
have received brief training (1-4 weeks) have shown effective outcomes, but more research is 
needed in this context. While task shifting and training the trainer have been pioneering in a 
global mental health context, these are not strategies used in developing countries alone. For 
example, the IAPT (Improving Access to Psychological Treatments) initiatives in the UK98,99 
resembles an advanced form of task shifting (rapidly educating a new category of mental 
health professionals called ‘Psychological wellbeing practitioners’), with its strengths and 
limitations that help us improve future large-scale endeavours. How can technologies be 
employed to train on a large scale and to maintain fidelity of treatment delivery? For 
example, models of training inexperienced clinicians with the aid of computerized guides 
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have been employed in primary care clinics in the United States, albeit on a much smaller 
scale than IAPT100. Research using the outcome and long-term follow-up data arising from 
such endeavours will yield many lessons as to how to increase access to psychological 
treatments worldwide. 
Technology is another important pathway by which to open the availability of 
psychological treatments93 (see also Section 5, Technology). The use of the Internet or mobile 
phones to provide psychological treatments combined with minimal individual support 
through e-mail or telephone has shown highly promising results in many studies in the 
developed countries101-106. However, given that a recent systematic review of online 
psychological interventions for mental health in LAMICs found only three such studies107; 
greater research efforts are required. This will be particularly important given that mobile 
phones are rapidly becoming increasingly available worldwide, as is the availability of the 
Internet - offering tremendous potential for education, assessment and treatment. In 2015, a 
median of 54% of the population across 21 emerging and developing countries reported 
either using the internet at least occasionally or owning a smartphone108. 
Low-intensity treatments delivered by computerized or mobile-based guided self-
help technologies present an ideal first-line or early option in a stepped care model of 
treatment. National guidelines are starting to propose the use of low intensity treatments as a 
first option to improve the availability of efficacious treatments (e.g., for bulimia nervosa and 
binge eating disorder109). Countries such as Sweden and Australia have led the way in 
research on Internet-based treatment and the implementation of low-intensity treatments 
within psychiatric care110-117, providing models that can be used or developed for improving 
access to care worldwide.  
Another major benefit of the internet is scalability of screening and assessment, 
which can readily be expanded to encompass the implementation of booster sessions by 
means of reminders, use of instructional movies and texts, as well as enhanced possibilities 
for long-term follow-up. Moreover, recent developments with regard to assessment in terms 
of continuous ambulatory assessment of symptoms may bring us much closer to the desired 
goal of assessments with high treatment utility, as they may help reveal the mechanisms of 
psychopathology and treatment on an individualized level (see also Section 8, Personalised 
models). Future research and implementation efforts should involve not only treatment, but 
 
 
40 
 
 
also prevention in an international context (see also Section 4, Prevention). As with 
treatment, prevention programs should target the core mechanisms that underlie the 
development of mental disorders, combined with culturally-specific risk and buffering factors 
(e.g., higher availability of social support and engagement of family in some 
contexts/cultures). 
Contextual factors play an essential role in any efforts to increase access to 
psychological treatments and are in themselves a topic for future implementation research. 
The involvement of all stakeholders is a key factor in scaling up services to ensure support 
and to facilitate sustainability118. Initiatives to improve mental health in LAMICs need to be 
rooted in the local society to assure sustainability, and in order to illuminate ways to 
maximise and achieve this. Engaging the local government, considering local legislations and 
traditions, involving patient organisations, creating conditions for continued education, and 
mutual exchange are important candidates. One area that currently demands research is 
efforts to help people who are refugees from war and persecution119. Not only are treatment 
developments imperative, but particular contextual factors require investigation (e.g., moving 
populations, multiple trauma experiences). 
 The stigma related to mental health problems is another barrier to improved access 
to treatment that requires further research. Understanding and addressing the relationship 
between religious/cultural beliefs and attitudes towards mental health is a crucial factor. The 
potential of highly available media such as radio and TV might have been underestimated 
with regard to attitudinal as well as behavioural change. As an example, there is clearly 
stigma related to talking openly about family planning among people living in poor 
communities in some LAMIC. The successful use of a well-designed TV-series to improve 
family planning and to reduce fertility rates in Mexico120 might constitute a good example of 
the effective application of such strategies to reduce stigma. The capacity of such strategies to 
combat the stigma related to mental health and seeking treatment for mental health problems 
warrants investigation. Another example is the “Headspace” initiative in Australia 
(https://www.headspace.org.au) which provides a model that could be adapted to different 
cultural contexts and norms with the goals of decreasing the stigma of mental illness and 
facilitating access to treatment. 
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The economic aspects of international mental health efforts should also be subject to 
more rigorous research efforts. Current evidence from the UK121 suggests that the payoff for 
psychological treatment approaches such as early intervention for psychosis, conduct disorder 
and suicide prevention has a ratio higher than 10 (i.e., for every £1 invested in such 
intervention, there will be more than £10 benefit). As estimated by the World Economic 
Forum, the cumulative global impact of mental disorders in terms of lost economic output 
will be US$16 trillion over the next 20 years122. Almost any estimate of the costs and benefits 
of investment on mental health research points in the same direction123. Although costs may 
increase in the short run, the benefits are much larger in the longer term. Future research 
designs should include cost-effectiveness analyses regarding the broader provision of 
psychological treatments in resource-limited settings, both in developed and developing 
countries.  
Research collaboration and exchange between cultures 
Focusing on international mental health in order to bring about improvements in 
psychological treatments would best be enabled by a mutual exchange of knowledge, 
experience and expertise between disciplines and across geography (see also Section 7, 
Training). Opportunities for students and professionals (both scientific and clinical) from 
different parts of the world to visit one other to learn about conditions for, and challenges in, 
improving access to psychological treatments in contexts other than their own may prove to 
be a key factor for creating the enthusiasm and lasting collaborations needed to develop 
sustainable interventions. Such an exchange might also facilitate cross-cultural comparisons 
that might contribute to further fundamental understanding and more efficient prevention and 
treatment of mental illness.    
Panel 6. Example Directions for Future Research to Improve Access to Psychological 
Treatments Worldwide 
 Build brief, flexible, modular and efficacious treatments which are streamlined 
based on knowledge from research on mechanisms of action in psychological 
treatments 
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 Use the knowledge regarding mechanisms of action of psychological treatments to 
derive treatments aligned with the local needs, priorities, traditions, and cultural 
factors specific to the environment in which the treatment will be delivered 
 Investigate how much education and training is needed for persons without or with 
limited previous experience of work within mental health to acquire proficiency to 
deliver basic psychological treatments as lay counsellors in a sustainable way 
 Investigate how new models of delivery of psychological treatments can be scaled 
up in a sustainable way since the long-term sustainability of most models is unclear 
 Investigate the use of media such as TV, Radio, and Internet to combat the stigma 
related to mental illness 
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3. With what? The potential for synergistic treatment effects: using and developing 
cross-modal treatment approaches 
 
Overview: With what 
Both pharmacological and psychological interventions are commonly recommended 
as first line treatments in psychiatry and the potential for enhancing treatment action through 
combination approaches has started to attract research interest. However, the optimal 
method for treatment combination is far from clear and requires dedicated research in 
preclinical, experimental medicine models and randomised controlled trials. We advocate 
that such an approach should consider the potential for synergy between key mechanisms of 
action across different treatment modalities and consider these treatments within the same 
research framework.  The potential for negative effects of treatment combinations should also 
be a priority for investigation in future research programs. 
 
Creating synergy and avoiding harm with combination treatments 
An individual with a mental health disorder (or comorbidities thereof, see Section 8) 
is likely to receive a combination of different treatment approaches as part of his or her care, 
often including psychological therapies, as well as different types of medication and social 
interventions, see Panel 7. However, current clinical guidelines remain largely silent about 
combination treatments. Meanwhile, the vast majority of research also focuses on a single 
treatment at a time, often with the presence of another treatment as an exclusion criterion to 
participation in randomised controlled trials (although see also meta-analyses of existing 
combination treatment studies)124-125. Clearly, given the sheer number of possible treatment 
combinations there is much yet unknown, and no guiding framework exists. As such,  the 
generalisation of research based on single (rather than combined) treatments to the typical 
clinical reality of combination in practise lacks validity. However, this state of the literature 
nonetheless opens exciting basic and clinical science questions about what does happen when 
psychological treatment is combined with other therapeutic approaches. 
Empirical studies suggest that there may be small benefits, for example, when a 
psychological treatment (such as cognitive behavioural therapy, CBT) and a pharmacological 
treatment (such as a selective serotonin reuptake inhibitor, SSRI) are combined in the acute 
treatment of emotional disorders including depression126. However, the longevity of effects 
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after treatment discontinuation may actually be reduced in some cases. For example, in the 
treatment of anxiety disorders, posttreatment relapse has been reported to be higher in 
patients who also received benzodiazepine or antidepressant treatment during CBT than in 
those who received CBT alone or in combination with a placebo127,128. Such findings 
emphasise the importance of capturing clinical effects after treatment end as well as during 
acute response, and also of focusing on potential mechanisms which could underlie these 
differential outcomes (see synergistic vs harmful combination effects Panel 7). 
For the most part, combination treatments in the clinic are driven pragmatically; for 
example, a client may receive two effective treatments, often with each from a different 
practitioner (e.g., a clinical psychologist and a psychiatrist). Such an approach contrasts with 
the attempt to combine treatments based on a mechanistic understanding or model. The hope 
is that scientifically informed combination treatments have the potential to create synergy and 
to support a better therapeutic response than either offered alone. Such approaches may be 
used to potentiate the mechanisms that are theorised to support a therapeutic effect or to 
overcome the limitations or barriers to a particular mechanism applied on its own (see Section 
1, Mechanisms). Interventions that are delivered together with psychological treatments may 
cover multiple modalities and may include the addition of pharmacological agents, 
neuromodulation, social, nutritional, or other forms of psychological intervention such as 
computerised training (e.g., cognitive bias modification, CBM). 
 
Panel 7. What is a Combination Treatment? 
 Combination treatment: the application of two or more types of intervention in 
patient groups, which have been specifically assessed for efficacy in combination. 
In the current context, we refer to the combination of psychological treatments with 
other types of interventions, across modalities, including the addition of 
pharmacological agents, neuromodulation, social, nutritional, or other forms of 
psychological intervention such as computerised training 
 Synergistic versus harmful combination treatments: some treatments may work 
well together and have greater efficacy than either applied on its own. For example, 
the use of a pharmacological agent to improve learning has been hypothesised to 
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enhance the retention of cognitive behavioural therapy’s benefits58, although see129. 
By contrast, some treatments may impair efficacy in combination.  For example, 
patients who receive benzodiazepines during psychological treatment may show 
reduced longer term benefits of CBT after drug discontinuation128 
 Patient perspective: the views, acceptance and opinions of the individual receiving 
the treatment can influence its effects. Patient preference needs to be considered in 
formal research programs that attempt to bridge the psychological-pharmacological 
divide 
 Pre-clinical: research using animal or human models is needed to understand key 
mechanisms and the effects of novel interventions before translation to clinical 
research programmes. 
 Back translation: The success of translational research depends in large part on the 
validity of the experimental model used to mimic the disorder in the laboratory 
 Back translation is used to describe the use of evidence from clinical research and 
experience to drive, test and refine the development and validation of animal and 
human preclinical models 
 Experimental medicine / experimental psychopathology: the use of a model, 
typically in humans, to explore key mechanisms and processes that are 
hypothesised to be important for treatment action in psychiatry. These models can 
be used to screen novel treatments and to refine their application prior to full 
clinical testing 
 
Utilising contemporary cognitive neuroscience research to boost psychological interventions 
Research focused on boosting the effects and retention of psychological treatments 
have utilised recent developments in neuroscience and experimental psychology88. 
Understanding the molecular basis of memory processes provides key targets that may be 
manipulated to facilitate extinction, reconsolidation of memories and learning which are key 
components of many psychological treatments, and operate across a number of disorders59,130. 
As such, drug treatments which are able to facilitate extinction of fear associations, reduce 
reconsolidation of troublesome aversive memories or enhance retention of more positive 
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memories or experiences during therapy may have a useful role in combination with 
psychological treatments. 
Augmentation of existing psychological treatments. There has been growing interest in 
the use of drugs targeting the glutamatergic system (such as d-cycloserine) to facilitate 
underlying processes of extinction and retention during exposure therapy in anxiety disorders 
such as agoraphobia, social anxiety and post-traumatic stress disorder58. However, identifying 
the factors which may moderate this benefit is challenging, and a recent Cochrane review 
found no evidence that d-cycloserine vs placebo conferred any advantage overall when 
combined with CBT in the treatment of anxiety disorders129. Direct brain stimulation 
techniques such as Transcranial Magnetic Stimulation (TMS) applied over the medial 
prefrontal cortex (implicated in extinction and inhibition) has been reported to modulate 
conditioned fear learning and extinction in healthy volunteer models131. It is hoped that the 
use of add-on treatments with effects on underlying mechanisms of learning and memory 
might speed up treatment effects, reduce the number of treatment sessions needed, or even 
help the longevity of effects. However, the field is also young and has challenges; it requires 
understanding the best methods to facilitate learning in an area where much is still unknown. 
For example, the optimal parameters for supporting learning pharmacologically or through 
neuromodulatory devices are elusive and require dedicated strategic focus to support 
preclinical work in humans and animal models58 see also Section 1, Mechanisms. 
A focus on mechanistically derived combinations also requires understanding and 
predicting the effects of a psychological treatment alone and in combination. For example, 
enhancing learning by pharmacological means (i.e., DCS) in an exposure treatment which has 
failed or where extinction has not occurred would be expected to have counterproductive 
effects; i.e., to strengthen poor outcomes. These complexities underscore the necessity and 
potential impact of elucidating the mechanisms of treatments in isolation and in combination 
(see Section 1, Mechanisms). 
The need for better pre-clinical models. These observations highlight the critical role 
for preclinical and experimental medicine models in understanding both the key processes 
and mechanisms that are important for treatment combinations and assessing early signals of 
efficacy for future clinical testing. While animal models were key to psychological treatment 
development in the 1950s and 1960s, translation has been less common in recent decades. 
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Animal models are commonly used in the pharmaceutical industry to screen novel agents, but 
rarely use a combination approach - i.e., by testing the effect of a drug together with a 
psychological intervention. This may lead to the early rejection of a drug which may have 
weak effects on its own but which may be useful clinically in an adjunctive role with 
psychological treatments. 
To support this endeavour, we therefore need strategic focus and funding avenues for 
mechanistically-informed treatment combination approaches in animal and in human models. 
We need to enhance the back translation of findings from the clinic to these models and 
stimulate interest in using combination models to assess novel treatments including drug 
development within pharmaceutical industry. Research in this area needs to incorporate 
measures which can assess and predict when and for whom combination treatment will be 
helpful. Regulatory support for this approach (from the FDA and EMA), linked to approval 
and licensing of agents, will be required to allow pharmaceutical companies to develop and 
test these kinds of combined treatments both to facilitate potentially beneficial combinations 
and to reduce potentially harmful ones. 
 
Unifying approaches and measures across treatment research 
Treatment combination across modalities can be limited by the barriers between 
researchers, clinicians and funders operating within these treatment approaches. The 
framework, language, and level of analysis are often different, making it difficult to see 
natural synergy. However, exploring treatments using a common framework may help to 
reduce these barriers and lead to novel hypotheses unpredicted by either approach alone.  For 
example, recent studies have used measures across fields to understand treatment effects, 
such as using neuroimaging to understand and predict therapeutic response to psychological 
treatments132 and employing psychological outcome measures to explore the effects of drug 
treatment133. 
As an example, the focus on antidepressant drug action has traditionally been 
considered at a molecular, cellular or chemical level, but there is increasing evidence that 
antidepressants affect core psychological processes that are important in depression before 
therapeutic effects are observed, and which may help explain their later clinical actions in 
depression (see133, Figure 1). Antidepressants increase the relative processing of positive vs 
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negative information early in treatment which may be important in the recovery process from 
depression as the patient experiences more positive feedback and reinforcement, countering 
the negative biases that are theorised to play a key role in maintenance of the disorder134,135. 
However, a key barrier to the successful translation of these effects into clinical 
benefit is the need for interactions with the environment. If a patient is socially isolated or in 
a particularly toxic environment, then increased positive bias and processing would be 
expected to have only limited effects. In line with this, Shiroma et al.136reported that 
increased positive bias induced with antidepressant drug treatment interacted with 
interpersonal support in the patients’ environment to predict therapeutic response (see Figure 
2). This kind of inter-disciplinary approach therefore has the potential to generate new 
hypotheses concerning combination treatment which would not have been predicted from 
either approach alone. Using this example, it is predicted that combining antidepressant drug 
treatment in its early phases with a psychological intervention134 which has the potential to 
increase interaction with the environment (such as behavioural activation), may remove a 
barrier to successful antidepressant drug treatment (see Figure 1). 
To facilitate interdisciplinary combination approaches, therefore, increased 
communication and translation are key. Greater collaboration and joint meetings, the use of 
similar assessments and measures and joint funding initiatives will help support this aim for 
improved combination treatments of the future. This requires organisations, funding bodies 
and researchers to work together, but the results will no doubt be exciting. An example of this 
followed the joint symposium recently presented at two very different meetings (the British 
Association for Psychopharmacology (BAP) and the British Association for Behavioural and 
Cognitive Psychotherapies (BABCP). This symposium, supported by the charity MQ: 
Transforming Mental Health, focused on the divide between psychological and biological 
treatment development and stimulated approaches to start to bridge the gap and align research 
strategy137. We need to build on this exciting initiative, call researchers across fields and set 
strategic funding to strengthen this early promise. 
 
Testing the efficacy of combination treatments 
Developing and assessing the efficacy of combination treatment also raises 
complexities for trial design and methodology (see also Section 6, Trials). Treatment trials 
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that compare active vs control treatment often require large sample sizes to have sufficient 
statistical power to isolate true effects from demand or placebo effects. Exploring interaction 
effects in comparison with individual treatments can require even larger sample sizes, 
depending upon study design. In particular, the effects of two treatments will often be 
assessed in isolation, in addition to their combination leading to a factorial design with 4 
groups (treatment 1 + placebo vs treatment 2 + placebo vs treatment 1 + treatment 2; placebo 
+ placebo). Mechanism studies in particular also need to consider possible state dependency 
of learning; i.e., that memory will be enhanced if tested in the same vs different state, 
including internal states produced by a drug138. This field of combination treatments will 
therefore benefit from a number of approaches and from testing effects at different time 
points and under multiple conditions.   
Experimental medicine can be used to test hypotheses in smaller controlled studies 
and using surrogate markers of treatment success. This approach has revealed key effects of 
both pharmacological139 and psychological140 treatments used in anxiety disorders on the 
same underlying cognitive processes. This approach has been used to explore the effects of 
combined treatment. For example, the effects of pairing computerised cognitive bias 
modification training with brain stimulation of the Dorso-Lateral Prefrontal cortex (DLPFC) 
was assessed using reactivity to a stressor as a proxy marker of efficacy in a healthy volunteer 
model141. The effects of cognitive bias modification and SSRI treatment alone and in 
combination have also been explored using the same outcome measure along with effects on 
negative memory bias, showing surprisingly that the combined effects could be worse than 
either applied in isolation in healthy volunteers142. Early changes in these measures are 
associated with later therapeutic benefit in patient groups136 and can therefore be used to 
guide initial proof of principle studies for treatment combination and to reject those which 
have little therapeutic promise. Combinations which appear successful using these surrogate 
markers can then be put forward for the next stage of clinical assessment, typically in a 
randomised controlled trial, with sufficient statistical power, and appropriate control 
conditions. This approach may be supported by big data approaches in which the data are 
collected under more naturalistic conditions (such as large scale analysis of medical records 
or prescribing patterns see Figure 2). Particular treatment combinations and timing of 
treatment combinations may be isolated by pattern analysis from large data sets. To facilitate 
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this, it is important to standardise assessments and the treatment elements applied so data can 
be combined and explored together. For further discussion of combination treatments, see 
also Section 8 (and Panel 18) on personalised medicine approaches. Therefore, the 
triangulation of experimental medicine, randomised controlled trials and big data 
analysis will be necessary to develop, assess and understand combination approaches of 
the future. 
 
Breaking down barriers: Psychological and biological treatments can tap into the same core 
processes 
Patient preference is also important to consider when evaluating the effects of 
combination treatment. Individuals often express a preference for either psychological or 
pharmacological treatment, and so the combination may be a difficult choice for some. This 
division underscores the view mirrored across society, clinical practice, and science that these 
are different processes and approaches; i.e., that there is a dichotomy between a 
psychological or biological view of mental health disorders. This view is challenged by 
evidence that psychological and biological treatments tap into the same core processes and 
represent different methods rather than different concepts133. Challenging these assumptions 
and creating more synergy at multiple levels (including the public, clinicians and scientists) 
will therefore be a critical step towards more optimal development of treatments. As part of 
this, the ethical implications of combination treatments and their development should be 
incorporated along with these areas for research strategy. Finally, we also need to consider 
the attribution of treatment effects from the patient’s perspective. For example, if any benefits 
from combined treatments are attributed to the medication, then the long term advantage of 
CBT can be lessened143. Studies to characterise attribution bias in combined treatment 
approaches and consideration of the strategies which may be effective in reducing these 
effects is a key priority for future work, see Panel 8.   
 
Panel 8. Example directions for Future Research in Combination Treatment 
Approaches 
 Development and validation of preclinical animal and human models for proof of 
principle studies and mechanistic focus in combination treatment research 
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 Elucidating the optimal parameters for enhanced learning with drug treatment 
approaches and the consideration of individual differences in this response  
 Stimulating pharmaceutical companies to develop and assess novel therapeutics in a 
combination role with psychological interventions. Fostering understanding of this 
approach within the regulatory community. 
 Clinical studies informed by proof of principle work to test the efficacy of 
treatments alone and in combination across disorders 
 Consideration of the potential harmful effects of combination treatment for 
treatments which work well in isolation including a focus on attribution bias and 
long term outcome. 
 Research on the views and acceptability of combined treatments in psychological 
disorders and the importance of patient preference and views about treatment for 
their clinical actions. 
 
Figure 1: Antidepressant drugs are hypothesised to work via early changes in negative 
affective bias, i.e., by reducing the influence of this key maintaining factor in depression133. 
This raises the possibility that psychological treatments could be used in combination to a.) 
boost effects of antidepressants on negative affective bias and b.) facilitate the translation of 
effects on bias into clinical action, via increased interaction and exposure to social and 
emotional cues.  
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Novel treatment or 
combination
Experimental 
medicine model to 
test effects on  
markers of efficacy
Discontinue 
development in 
current form
Randomised 
controlled trial in 
patient cohort
Does not meet criteria
Meets criteria
Use information to change treatment
Big data 
approaches
Figure 2: Using experimental medicine models for earlier assessment of efficacy of novel treatments and combinations.  
The use of surrogate markers within experimental medicine models can be used to screen new treatment combinations 
in small groups of patients or volunteers.  This information is used to refine decision making about subsequent RCT 
application and design. If insufficient evidence of efficacy is seen in the model, this information can be used to change 
treatment focus, dose/duration or target.  If pre-set criteria are met, the efficacy can be assed using RCT designs.  Big 
data approaches may be useful to highlight particularly promising treatments or combinations and provide additional 
evidence of efficacy from naturalistic data capture methods
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Increased 
perception 
of positive 
cues
SSRI
Positive 
Environment
Negative or 
isolated 
Environment
No increase 
in perception 
of positive 
cues
Positive 
Environment
Negative or 
isolated 
Environment
Treatment Early psychological effect      Moderation by environment      Clinical response
Figure 3: Increased perception of positive cues has been associated with later clinical response with SSRI 
treatment but this effect is moderated by environmental and social factors.  Therefore, increased 
positive bias is only associated with improvements in depression in the context of a relatively supportive 
or positive environment.  In the absence of changes in emotional bias, environment had little impact 13
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4. When in life?  Psychological science, prevention and early intervention: getting it 
right from the start 
 
Overview: Prevention - and a developmental perspective 
Opportunities for prevention and early intervention for mental health problems exist 
across the lifespan. However, the early years of life represent perhaps the greatest 
opportunity to set a path to good mental health. This requires both population-based change 
and the accurate identification of those at risk – in both approaches there is need for effective 
and safe interventions. Currently many widely used approaches have limited or no scientific 
underpinning. The rigorous and sustained application of psychological science approaches 
to this area of practice is critical and offers enormous promise. The focus of this section is 
primarily on children and young people.  
 
Prevention and early intervention 
Opportunities for prevention and early intervention for mental health problems exist 
across the lifespan. The imperative to reduce risk factors across the population, and to 
intervene at the earliest point when symptoms, or precursors, of mental distress occur makes 
human, societal and economic sense144-146. Psychological science can inform and underpin 
the development of these early preventative interventions, even where the risk factors are 
social in origin. 
 
The early years of life 
The early years of life, right from conception, through to childhood and adolescence 
represent a wonderful opportunity to set a path to good mental health. Most psychopathology 
has its origin or onset before the age of 18 years147. There is enormous potential to either 
prevent mental health problems from the start, or to intervene early to reduce the current and 
future impact of any mental health problems that do occur. The greater plasticity of the brain 
during childhood, and the nature of the emotional and behavioural responses of a child, mean 
that the potential to intervene successfully and powerfully may be greater than at any other 
point in life. At the current time there is a potentially greater role in early life for 
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psychological approaches compared to pharmacological and other physical interventions, 
although many interventions, such as nutritional approaches, remain under-researched. For 
psychological interventions to make significant inroads into the effective prevention of 
mental illness some key requirements for interventions and new scientific and clinical 
challenges have to be met2. The following sections outline some of these requirements and 
some of the key challenges and questions that remain to be tackled.  
 
Requirements and challenges for prevention and early intervention 
Panel 9. Psychological Treatments: What are Preventive and Early Interventions? 
Prevention: often defined as those interventions which are conducted before people 
meet formal criteria for a disorder148. Three types are described: universal prevention, 
which is aimed at the general population or parts of the general population, regardless 
of whether they have a higher than average risk of developing a disorder (e.g., school 
programs or mass media campaigns); selective prevention which is aimed at high-risk 
groups, who have not yet developed a mental disorder (an example would be the Nurse 
Family Partnership programme developed in the US which initially aimed to prevent 
later psychosocial adverse outcomes for women and their children in socio-
economically deprived areas149; and indicated prevention which is aimed at individuals 
who have some symptoms of a mental disorder but do not meet diagnostic criteria (an 
example would be the intervention developed by Rapee and colleagues for parents of 
pre-school children who are at risk of anxiety disorders, which has potential long-term 
effects from a brief intervention150. 
 
Preventive approaches in childhood and adolescence (see Panel 9) will often require 
the effective identification of risk factors or at-risk groups (unless an intervention is going to 
be delivered to the whole population). Existing preventive strategies to reduce mental health 
problems are often very clear in the identification of risk factors for future disease or 
disorder144. A range of key early-life risk factors have been established; including exposure to 
severe adversities such as child maltreatment, disturbed parenting, parental substance misuse, 
exposure to domestic and other violence, and loss events, such as serious illness in, or death 
of, a parent151. Identification of such risk factors is important in selected and indicated 
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prevention approaches, and identifying those young people who may potentially benefit from 
intervention most is a key first step. However, knowledge to date is by no means complete, 
and further research is needed on these and additional risk factors, as well as interactive effect 
between risk factors. 
Identifying and elucidating these risk factors is not sufficient. For change to occur 
there have to be effective and acceptable interventions. These may target modifiable risk 
factors, or may use other theoretical approaches to change, including tackling key 
psychological mechanisms. This remains a significant gap in our knowledge as many early 
interventions do not have sufficient evidence to be considered to be effective. Developing and 
testing early interventions that may be effective in reducing future risk of psychological 
illness is a fundamental and largely unmet challenge. 
 
Current research limitations regarding early interventions 
It is often implicitly assumed that any kind of early intervention is better than nothing. 
However, this is not the case, and almost any intervention which can actually do or change 
something has the potential for harm if used in the wrong circumstances; for example, as has 
been discussed in the area of eating disorders152. The possibility for harm is often overlooked 
and is probably one of the key blind spots in the field of prevention of psychological 
problems, particularly when translated into policy. It is critical to acknowledge that not all 
interventions are the same: even interventions with overlapping appearance or content can 
have different effects153.  
There is a relative paucity of evidence for psychological treatments in many areas of 
child and adolescent mental health practice, particularly for very young children, presenting a 
great opportunity for future research. This is a promising area as where sufficient high-quality 
evidence does exist, differences in treatment effectiveness are emerging55,154. A related 
consideration is that an intervention may not have the same treatment effect in every setting 
or with all individuals equally (see for example apparently contradictory findings for the 
Family Nurse Partnership intervention155,156). Disentangling these challenging problems is 
made more difficult when the components of a psychological intervention are not clearly 
specified or publically available; this is often for commercial or some other protective reason. 
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Whilst these may be important imperatives to consider, they hamper efforts to identify and 
replicate the critically effective components of any intervention.  
A further significant challenge is a lack of understanding of the mechanisms by which 
intervention occurs in many preventive and early interventions. As set out in Section 1 
(Mechanisms), this is crucial to development of new and more effective methods of 
successful treatment. However, in a preventive and developmental context, this is likely to 
more fluid than at other points in life. For example, different mechanisms may operate at 
different points in childhood, and each of these may be different from the mechanisms 
operating in adulthood, even for the same condition or presenting problem (see also section 8 
Complexities). There are relatively few well-studied examples of this, although some are 
emerging, such as the lack of evidence for specific cognitive biases for emotional stimuli in 
young children at risk of anxiety disorders that have been identified in adults with anxiety157. 
In early childhood there will also be a need to go beyond the individualised mechanisms 
suggested in the RDoC explanatory constructs (see Section 1, Mechanisms). For example, 
other mechanisms, existing in the social world of young children may open critical pathways 
to help change precursors of psychopathology, such as via the early relationships, or 
attachments, that children form to their parents or carers (see also the social processes domain 
of RDOC). Parental sensitivity has been shown to be a key mechanism of change in for 
example the context of attachment158,159, although the detailed processes which might then 
lead to the development of psychopathology largely remain to be elucidated. It is clear that a 
better understanding of mechanisms underlying treatment gains may also be critical to any 
step-change in effectiveness of prevention and early intervention.  
 
Making interventions stick - persistence of effects 
One further challenge for preventive and early intervention approaches, which is 
shared with many other forms of psychological intervention, is how to make interventions 
“stick” - that is, not only how to make the effects of psychological treatment last beyond the 
end of the treatment, but also how to make them generalise to other areas of life functioning. 
There are a number of interventions which have demonstrated efficacy in randomised 
controlled trials at the end of treatment (see some examples below), but it is an all-too-
common experience that these treatment effects dissipate as people are followed up for 
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months or years (e.g.,160). There are relatively few psychological interventions that have 
convincing evidence of sustained benefit. We do need longer-term evidence (see Section 6, 
Trials), but also developments in psychological science to inform how to make our 
interventions stick. Further, work is needed to develop approaches to take psychological 
interventions outside of the therapy room, which may make interventions more widely 
available and acceptable, and make effects more likely to generalise to everyday life 
functioning. The use of technologies may aid in this regard (see Section 5, Technologies). 
One example, which a number of research groups are tackling, is how to prevent or treat early 
signs of depression using gaming and other technologies161. A further approach is to take 
interventions out into schools162. Both of these types of approaches have utilised primarily 
cognitive behavioural interventions to date, although others, such as Interpersonal Therapy 
(IPT) also show promise for depression in children and young people.     
 
Positive examples for the future 
Despite these challenges, there are areas in which promising evidence is accumulating 
for prevention and early intervention. Three examples are described briefly in panel 10 as 
they provide pointers to the way in which future research and clinical practice might more 
effectively develop in this area. 
 
Panel 10. Examples of Promising Preventive and Early Intervention Approaches 
Example 1: During infancy, there is accumulating evidence that brief, focussed 
interventions such as ViPP (Video Feedback to Promote Positive Parenting: for example, 
see163,164) can improve parental sensitivity and the child’s attachment relationship with 
their primary caregiving parent. This draws on both attachment theory and social learning 
theory. There is some, although limited, evidence of effects on child behaviour as well for 
this intervention, which is largely lacking for other video feedback parent-focussed 
approaches at the present time. 
Example 2: In slightly older pre-school children (aged 3-5 years), an intervention for 
the parents of children with increased risk of anxiety disorders (identified by having high 
levels of behavioural inhibition) has been shown to reduce the risk of subsequent anxiety 
disorders.  This intervention was brief (6 sessions), and used an educational approach with 
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some behavioural components focussed on exposure. Effects were still seen in the longer-
term (11 years later), although only convincingly in girls, and shown to be cost-effective 
using Australian criteria for cost-effectiveness150,165. 
Example 3: In school age children there is consistent evidence of benefit of parenting 
groups based on social learning theory, such as the ‘Parenting Programmes’ to improve 
child behaviour166. Longer-lasting benefits have been demonstrated in some studies, and 
economic modelling studies point to societal, financial and individual health gain167. 
 
These three groups of interventions are important because they highlight that 
preventive intervention and early intervention are possible from very early in life, and that 
longer-lasting benefits are possible. All three interventions are derived from scientifically 
rigorous, sustained approaches to intervention development, which are critically informed by 
theory. They also highlight some of the challenges mentioned above, including that we still 
have relatively limited understanding of which sub-groups are most likely to benefit from 
which interventions. Other preventive/early interventions do exist, with varying levels of 
research evidence to support them in a range of psychological/psychiatric conditions. 
However, the three examples above offer particular pointers to a rigorous approach to 
intervention development and delivery that is more likely to benefit children and young 
people in the long run.  
 
Prevention of mental disorders in adults 
In this section we have focused on prevention of mental health problems in children 
and adolescents, because most mental disorders have their origin in early life147. However, 
there is a broader area of research on the possibilities to prevent the onset of mental disorders 
in adulthood that we briefly want to mention here. Prevention of mental disorders is 
considered to be one of the main challenges for the future of mental health care, because of 
the high burden of disease of mental disorders for individual and societies, the relatively 
small effect of current treatments and because of the enormous societal costs of mental 
disorders once they have emerged168. 
In the past two decades a growing number of randomized controlled trials have shown 
that it is in some cases possible to prevent or at least delay the onset of mental disorders in 
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adolescents and young adults, especially depression and psychotic disorders. Psychosocial 
preventive interventions, typically based on psychological treatments such as cognitive 
behaviour therapy (CBT) or interpersonal psychotherapy (IPT), have since then been tested in 
at-risk populations and in people with subthreshold symptoms of depression or psychosis, 
who do not meet diagnostic criteria for a full-blown mental disorder. Results of these 
interventions (now across several dozens of randomized trials) show them to be effective in 
reducing the incidence of new cases of depressive disorders at follow-up by about 20 to 
25%169,170, and in preventing or delaying the onset of about 50% of psychotic disorders in 
those at high risk for developing a psychotic disorder (171, see also the influential work in 
Australia published by McGorry and colleagues, e.g.172). Because of these promising results, 
preventing the onset of mental disorders is one of the most promising areas in which research 
on psychological interventions can help to reduce the disease burden of mental disorders. 
 
The challenges ahead 
Clearly, future research is demanded to expand our repertoire of approaches. These 
approaches need to be theory-driven and rigorously trialled (see Section 1 Mechanisms and 
Section 6 Trials) to expand the range of mental health disorders that can be addressed. This 
includes early preventive approaches focussed on infancy and childhood, and also 
interventions through adolescence, when young people begin to present with many of the 
common mental health problems that will affect them through adult life. 
Particular attention needs to be paid to ensuring that interventions can produce effects 
that may have lasting benefit for children and adolescents, and significant efforts need to be 
made to develop or adapt interventions so that they can be used across a range of settings and 
can be accessible on an international scale173 (see Section 2, Mental Health Worldwide). 
Preventive, early intervention approaches for mental health problems face particular 
challenges in terms of demonstrating effectiveness and being applied consistently and 
thoughtfully to everyday practice in healthcare, however they offer huge potential for health 
benefit. The existing good examples considered above provide optimism for future 
developments in this challenging area, see Panel 11. However, we still need to look carefully 
at the limits of effectiveness, and also at the potential for harms caused (for example, 
potential negative effects of screening and classifying high risk groups and unnecessary 
 
 
61 
 
 
treatment offered to young people with only temporary distress or symptoms, or harmful side 
effects of individual psychological treatments).  
Given that evidence is now accumulating that some preventative psychological 
treatment approaches aimed at adulthood too do indeed help to (i) prevent, or (ii) delay the 
onset of disorder, or (iii) reduce the incidence of recurrence of episodes, a focus here opens 
exciting and important areas for inquiry across populations and disorder types. Insights 
should be pooled across the age spectrum from the early years to older adults. Whilst there is 
still a long way to go before we will have widely-available and effective methods of 
prevention for mental health problems, the rigorous and sustained application of 
psychological science approaches to these areas of practice offers enormous promise. 
 
Panel 11.  Example Directions for Future Research in Prevention and Early 
Interventions 
 When are the optimal times to intervene to prevent mental health problems? 
 Who are the key “at-risk” groups to most effectively aim to intervene early or 
preventatively with? 
 What are the potential harmful effects of specific early intervention approaches? 
 How do we increase the “stickiness” of treatment effects – how do we make them 
last beyond the end of treatment? 
 How can we deliver interventions on the scale (including internationally) needed to 
reach at-risk children and youth? 
 How can insights from mechanisms of change help prevent or delay disorders, and 
reduce the recurrence of episodes? 
 How can we apply insights about prevention across the life span? 
 
 
 
62 
 
 
5. Technology: Can we transform the availability and efficacy of psychological 
treatment through new technologies? 
 
Overview: Technology 
Internet-based psychological treatments have made great strides across a broad range 
of mental health disorders. The rise of eHealth and mHealth approaches that use information 
technology (e.g., the Internet, virtual reality, serious gaming) and mobile and wireless 
applications (e.g., text messaging, apps) marks a new era for evolving psychological 
assessment and treatments. In brief, technological innovations offer considerable possibilities 
to innovate psychological treatments, to adjust them more to daily life and to the persons 
using them, and improve access to treatment. Further, such knowledge could be used to 
better understand how therapies work and to make them better and easier to use, so that 
more people can benefit from psychological treatments. However, developments should be 
theory-driven and properly evaluated, and interventions should be less based on traditional 
face-to-face therapies and be more interactive and based on available technical possibilities. 
 
Internet-based psychological treatments 
Dozens of randomized controlled trials have demonstrated the efficacy of Internet-
based therapies (see Panel 12) for a broad range of mental health problems. A growing 
number of meta-analyses show that these therapies are effective in the treatment of 
depression174, anxiety disorders175, sleep problems176, bulimia175,alcohol problems178, and 
problems such as pain and migraine179. Current Internet-based treatments can be seen as 
forms of self-help interventions that are conducted through the Internet, which means that 
patients learn how to apply a psychological treatment to themselves with the help of a coach 
or psychologist101. Direct comparisons between face-to-face interventions and guided Internet 
interventions suggest that there are no major differences in efficacy between the two 
treatment formats110.  
Panel 12. What Do We Mean by New Technologies? 
 Internet intervention: A (guided) self-help intervention delivered through the 
Internet 
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 A self-help intervention can be defined as a psychological treatment in which the 
patient takes home a standardized psychological treatment protocol and works 
through it more or less independently. Self-help interventions can be delivered with 
(guided self-help) or without human support (self-guided) 
 Although internet-based therapies can be defined as any therapy that is delivered 
with the help of technology (for example through chat sessions, skype, or email), 
most research has focused on Internet-based self-help interventions. Because most 
research has been conducted on Internet-based self-help interventions we will focus 
on these treatments. If we refer to Internet interventions, we mean these treatments, 
unless we explicitly say otherwise. 
 eHealth: the transfer of health resources and health care by electronic means 
(http://www.who.int/trade/glossary/story021/en; accessed April 15, 2016) 
 mHealth: The use of mobile and wireless technologies to support the achievement 
of health objectives180. 
 
Advantages of internet interventions. Internet interventions and the trials that have examined 
them have many advantages. They can save therapist time, reduce waiting lists, allow patients 
to work at their own pace, abolish the need to schedule appointments with a therapist, save 
traveling time, reduce the stigma of going to a therapist, and ease psychological help for 
individuals who are hard of hearing181. Furthermore, they may reach patients who cannot be 
reached with more traditional forms of treatment. Interventions  can also be relatively easily 
adapted to specific target groups, with a wide range of attractive audio-visual information 
with voices giving instructions in whichever gender, age, accent, language, and perhaps game 
format the patient prefers. Internet interventions are also probably more cost-effective than 
face-to-face therapies, but more health economic research is needed to verify this. 
From a research perspective these interventions also have numerous advantages. One 
major advantage is that internet interventions are much easier to conduct than are large 
randomized controlled trials (RCTs), (see Section 6, Trials). Specifically, recruiting patients 
and conducting Internet interventions is much easier and more efficient than conducting 
RCTs of traditional face-to-face psychotherapies. Larger randomized trials make it easier to 
examine effective components of interventions in dismantling studies, to examine moderators 
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of outcome, and to examine mediators and the working mechanisms of therapies (see Section 
1, Mechanisms). Such research will stimulate the further development of personalized 
treatments of mental disorders (see Section 8, Complexities). This approach also facilitates 
research that is traditionally complicated because of the large sample sizes needed, such as 
prevention trials aimed at the prevention of new cases of mental disorders182 (see Section 4, 
Prevention). 
Limitations of Internet Interventions. This new emerging field of Internet 
interventions has considerable promise to contribute to a further reduction of the disease 
burden of mental disorders. But there are also some limitations and challenges that have to be 
taken into account when this research area is expanded. The quality of interventions that are 
offered through the Internet is not certain and despite portals for evidence-based Internet 
therapies such as Beacon (https://beacon.anu.edu.au), the possibility that low quality 
therapies are offered remains an important threat. Beacon is a webservice at which a panel of 
health experts categorise, review and rate websites and mobile applications and is part of a 
suite of self-help programs, developed and delivered by the National Institute for Mental 
Health Research at the Australian National University (although it is unfortunately not 
currently being updated). It is also known that drop-out rates are higher in Internet-based 
interventions than in face-to-face therapies183 and it is not known whether patients who drop 
out get worse because of the intervention. It is sometimes assumed that internet interventions 
may affect the therapeutic alliance between therapists and patients, but most evidence 
suggests that therapies through the internet are at least equivalent to face-to-face therapy in 
terms of therapeutic alliance184. Furthermore, more research should be done on the long-term 
effects of Internet interventions, because relatively little research has focused on that 
(although the same is true for face-to-face psychological treatments). We also acknowledge 
that Internet interventions may also have unknown disadvantages, such as misunderstandings 
due to reduced communication channels in unguided interventions and schematization of 
contents. Finally, data security as well as privacy should be well-guarded for any intervention 
that is offered through the Internet, and this will only become more important when other 
new technologies (see below) become integrated into online interventions.  
Furthermore, despite increasing access, we acknowledge that the Internet is not yet 
accessible to many potential users around the world, and dissemination will depend on the 
 
 
65 
 
 
attitudes of possible users and health care professionals. However, even in LAMIC countries 
access to the internet and/or mobile phone is expanding exponentially (see Section 2, Mental 
Health Worldwide), although creative solutions (e.g., regarding literacy) may need to be 
taken into consideration. 
 
Other technological opportunities 
Most psychological treatment research has been conducted with what could be called 
“traditional” Internet interventions. In these interventions, patients sit behind their computer 
and work through self-help materials. Such self-help materials have often been very close in 
content to face-to-face delivered psychological therapy (e.g., CBT). Accordingly, it is as if 
hard-copy paper manuals are simply converted to computerised form sometimes with simple 
additional content such as video clips. But technological developments are occurring rapidly, 
and such advancements will no doubt expand the repertoire of learning methods (e.g., Serious 
Gaming, see below). Interventions can increasingly be offered through smartphones, smart 
watches, google glasses, virtual reality headsets, and all kinds of other innovative devices. 
Many of these devices have the advantage that they can be worn during daily life and can 
also collect information during daily life (“ecological momentary assessment”185 (see also 
Section 8, Complexities). Such information may considerably improve prediction models for 
individual patients and thus potentially improve treatments and increase the effect sizes of 
existing treatments. Computerized Adaptive Testing techniques assess symptoms online with 
greater sensitivity and specificity from fewer items186. Several “virtual reality” treatments 
have also been developed in recent years, mainly for anxiety disorders. In virtual reality 
therapies patients are not confronted with the real anxiety-provoking stimuli but with their 
virtual counterparts using real-time computer graphics, body tracking devices and other 
sensory input devices187. There is evidence that virtual reality interventions may be effective 
in the treatment of anxiety disorders188,189 although many of the trials conducted to date are 
small and are of suboptimal quality. A considerable number of studies have demonstrated that 
telephone-supported therapies are effective in the treatment of common mental disorders190. 
There is a rapid proliferation of mental health ‘apps’ which aim to offer a range of 
psychological interventions191. However, most currently available technology-based 
interventions (e.g., health apps) within eHealth and mHealth are characterized by lack of 
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health behaviour theory and evidence for the effectiveness192. Critical directions for future 
research will be to develop theory-driven interventions and evaluate their effectiveness - 
since the vast majority are yet to be tested in randomised controlled trials (although there are 
some exceptions)193,194 and may need specific adaptations to the design of randomized trials 
because of rapid technological developments195. Risks are also posed by widely available and 
untested products. In this young field, while efforts have started, the continued development 
of international approaches is needed to develop regulated approaches and procedures.  
The format of new technologies may allow new treatment techniques to be developed 
that were not part of pre-existing face-to-face psychological treatments (e.g., the traditional 
psychological treatment manuals converted by most Internet-based therapy to date) but offer 
novel information processing options (e.g., virtual reality exposure, and possibly 
interpretation bias training). Serious gaming, such as the Sparx program, also opens 
opportunities for interdisciplinary research and new methods of treatment delivery196. Serious 
games refer to those games with a purpose other than providing entertainment, in this case the 
delivery of a psychological treatment using game principles. Sparx is an interactive fantasy 
game designed to deliver cognitive behavioural therapy for the treatment of adolescents 
seeking help for depression. 
It is also very well possible that at some point the automated support of these new 
technologies can in some cases replace the therapist altogether (‘therapist-free therapy’197), 
and lead to better, personalised treatments (see also Section 8, Complexities). New 
technologies can also be useful in predicting the development and outcome of mental 
disorders. For example, mobile phones are available to monitor relationships between 
psychological risk and suicide ideation198, and there is evidence that certain phrases and the 
use of personal pronouns for example predict depression status in blogs (see also Section 9, 
Suicide), although we acknowledge that this may raise ethical concerns198. Because enormous 
quantities of data can be collected through mobile phones and other devices and can be 
connected with existing databases, datamining techniques may be helpful to predict the onset 
and course of mental disorders. Such data could aid the development of innovative 
psychological interventions that are much more integrated into the new technologies which 
are assimilated into the daily lives of patients. However, technology and data alone will not 
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suffice – endeavours are more likely to succeed if they are embedded in a sound theoretical 
framework to drive hypothesis alongside clinical knowledge. 
In brief, technological innovations offer considerable possibilities to innovate 
psychological treatments (see also Panel 13), to adjust them more to daily life and to the 
persons using them, and to use the knowledge to better understand how therapies work and to 
make them better and easier to use, so that more people can benefit from psychological 
treatments across the age range and worldwide. 
Panel 13. Example directions for Future Research with New Technologies for 
Psychological Treatments 
 Treatment and theory development: health behaviour theory informed technological 
treatment innovation across all areas of psychological treatments 
 Treatment evaluation: trials to evaluate the effectiveness of new products such as 
apps 
 Learning: Maximising and innovating learning methods during psychological 
treatment by fresh means of for example skills learning, habit change etc (e.g., via 
Serious Gaming) 
 Devices: the use of new technologies, like avatars, smart watches, Google glass, 
and other devices into existing psychological treatments to facilitate delivery and 
improve outcomes 
 Harnessing new technologies to advance methods by which to examine causal 
mechanisms,  refine treatments, and derive mechanistically-driven treatment 
approaches 
 Health monitoring: to enable big data capture to predict the onset and course of 
mental disorders 
 Personalisation of technology based interventions 
 Technologically aided preventative treatment approaches adapted across the age 
range 
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6. Trials to Evaluate Psychological Therapies 
 
Overview: Trials 
There are several key issues in the design and conduct of clinical trials for the 
evaluation of psychological therapies, and addressing these is essential for the development 
and innovation of evidence-based psychological therapies. These issues present some specific 
challenges, given the complexities of both the therapies being evaluated and the populations 
who are receiving them, as well as a number of opportunities for improvement. The 
challenges include improvements in standards for reporting clinical trials, specification of 
treatment protocols and inclusion/exclusion criteria, choice of outcome measures, 
measurement of adverse effects and preventing bias in trial design and analysis. The 
opportunities include the increasing role of service users and carers in all aspects of trial 
design and conduct, the developing methodologies for achieving consensus regarding 
research questions and outcome measures, the development of new methods for analysis of 
mediators and mechanisms and innovations in design of clinical trials (such as adaptive trial 
designs and mixed methods approaches that embed qualitative studies). 
 
 
Introduction 
There are several key issues in the design and conduct of clinical trials for the 
evaluation of psychological therapies. This is an area that is essential to the agenda for 
development and innovation in evidence-based psychological therapies, which present some 
specific challenges, given the complexities of both the therapies being evaluated and the 
populations who are receiving them, as well as a number of opportunities for improvement. 
These challenges and opportunities will be considered in the context of a current feasibility 
study (the COMPARE trial, ISRCTN06022197) and the potential for a subsequent definitive 
trial to evaluate cognitive behaviour therapy for people with psychosis in direct comparison 
to antipsychotic medication and a combined treatment, which is a research recommendation 
in the UK NICE guideline for treatment of psychosis in children and young people199. This 
trial has been chosen because it is complex and challenging to conduct for a variety of 
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reasons that will be described, and as such, illustrates many of the problems and potential 
solutions.  
Other important issues for psychotherapy trials include the selection of control 
conditions and outcome measures, the role of public and patient involvement, the inclusion of 
moderation and mediation analyses to facilitate identification and refinement of mechanisms 
and the development of new, innovative methods that are fit for purpose to answer the 
important questions that have been identified, see also Panel 14. 
Panel 14. What Terms are Used in the Context of Clinical Trials? 
 Clinical trial: An experiment to determine whether a treatment works, usually 
determined by examining effects on outcome measures. This can include: 
- A feasibility study: this is a small clinical trial which is conducted in order to 
determine whether it is feasible to do a larger clinical trial, which has 
sufficient statistical power to definitively answer a research question about 
treatment effectiveness. It focuses on the question of whether such a study 
can be done. 
- A pilot study: this is a small version of the main clinical trial, which focuses 
on evaluating the trial processes, such as recruitment, randomisation, 
treatment protocols and follow-up assessments. These trials can be internal 
pilots, where the data collected contributes to the larger definitive trial 
assuming there are no changes required, or an external pilot, where the data 
are analysed and set aside.  
- A randomised controlled trial: this is a study in which participants are 
allocated to a particular condition (usually a treatment ‘arm’) on the basis of 
random assignment in order to produce an equal distribution of measured and, 
crucially, unmeasured variables. Also, it ensures future treatment allocations 
are hidden from recruiters. The ‘controlled’ nature refers to using comparators 
(the conditions to which an experimental treatment is compared); these often 
include the best available treatment, treatment as usual (what routinely 
happens in clinical services), a treatment designed to control for factors such 
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as empathic human contact or a treatment with the putative ‘active’ ingredient 
removed (known as ‘dismantling’ designs). 
 Clinical Trials Units: these are specialist units that have expertise in centrally 
coordinating multisite clinical trials, in addition to trial design, data management, 
and trial statistics and health economics 
 CONSORT: The Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence-based guideline200, based on a systematic review of 
evidence regarding aspects of trial design and conduct that could contribute to bias. 
Using consensus methods, the developers produced a checklist of 25 items and a 
flow diagram, which aims to minimize bias and improve reporting of clinical trials 
 Sources of bias: There are many potential sources of bias that can influence the 
validity of a clinical trial. These include allocation concealment (whether future 
randomization could be guessed), adequate blinding of participants, personnel, and 
outcome assessors (although the first two of these are nearly impossible to achieve 
in a trial of face-to- face talking therapies, (though see also section 6 Internet 
therapies), amount of missing data and selective reporting of outcomes 
 Blinding: This refers to whether participants or staff are aware of the treatment 
allocation (e.g. do they know whether they are receiving CBT or treatment as 
usual). Note single blinding versus double blinding is a key difference between 
psychological versus pharmacological trials.  
 Protocolised treatment: A protocolised treatment is an attempt to standardize the 
delivery of a psychological therapy. It is often characterized by required processes, 
procedures and milestones as well as those that are prohibited. Some treatment 
protocols are very specific, prescribing the content of each session in a strict, at 
times modularised manner, whereas others are more flexible in order to account for 
the idiosyncratic, often complex, nature of presenting difficulties. The more rigid a 
trial protocol is, the easier it is to assess treatment fidelity and allow replication of 
the study. 
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The need to improve clinical trial methodology 
There is a need to improve the scientific rigor and transparency of clinical trials of 
psychological therapies, given that these are the cornerstone of evidence-based approaches to 
decisions about access to healthcare. In the field of mental health, such trials often have 
significant methodological shortcomings that result in low quality evidence. For example, in 
relation to CBT for people with psychosis, many of the earlier clinical trials were subject to a 
variety of problems: for example, many were not registered, which is a problem in the whole 
field of psychotherapy research201. This means that we cannot be certain that their primary 
outcomes were those originally intended, and raises the possibility of selective reporting of 
outcomes (i.e., focusing on those that were statistically significant), or even that negative 
trials remain unpublished; many did not attempt to maintain blinding in the raters, which 
increases the likelihood of bias; treatment protocols were broad and not based on a specific 
model, which makes assessment of fidelity and replication problematic. These limitations 
could be overcome by ensuring linkage between expert trial methodologists and statisticians 
and innovators in psychological therapy development. For example, accredited ‘Clinical 
Trials Units’, with their extensive experience of trial design and conduct, could coordinate 
with academic methodologists who are at the cutting edge of developments in trial statistics 
and methodologies202. In the past decade, for psychological treatment trials, in line with trials 
in other domains, there has been substantial improvement in the adoption of clinical trial 
registration and pre-specification of primary outcome including CONSORT criteria. Indeed, 
such issues are increasingly required by the leading journals and by ethical review boards. 
Particular adaptions for psychological trials need to be further developed, e.g., around issues 
such as double blinding which cannot be maintained with a therapist-delivered psychological 
treatment. 
 Relatedly, the potential negative effects of psychotherapy are increasingly being 
recognised and there is a need to document deterioration and adverse events during treatment. 
Negative effects that require recording range from worsening of existing symptoms to issues 
such as novel symptoms, poor therapeutic relationship and perceived coercion203. Such 
adverse events are present both in traditional psychotherapies as well as internet-based 
interventions204. A procedural model and checklist are available for clinicians and 
researchers, and the detection and management of such adverse events in treatment trials is 
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considered a sign of good rather than bad practice205. Further research is needed so that 
formalized measures of possible harms/“side effects” of treatment trials are the rule rather the 
exception in psychotherapy research (see206,207).   
To ensure that psychological therapy trials are credible, it is important to meet the 
minimum standards expected from other fields (e.g., pharmaceutical trials). However, we also 
have an opportunity to develop our own standards, which ensure superior trial design, 
conduct and reporting, that other fields could aspire to meet. Over more than a decade, 
researchers who have studied psychological therapy in trials have embraced trial registration, 
pre-specification of statistical analysis plans and trial protocols, independence of statistical 
analyses from the psychological innovators and adherence to CONSORT’s reporting 
recommendations200. Yet, not all criteria can be met given that, for instance, double blinding 
in these types of studies is not usually possible. Some of these factors inherently bias the 
judgement of quality of evidence against psychological therapies in comparison to drug trials. 
For example, drug trials are usually judged to be superior to psychological therapies on the 
issue of blinding, since in a double blind trial it is alleged that the clinician, the independent 
assessor and the participant are unaware of whether they are receiving active drug or placebo, 
whereas in a psychotherapy trial, both clinician and participant are aware of what treatment is 
being delivered and received. 
 It is interesting to note that the issue of double blinding can be problematic not only 
for psychological but also pharmacological treatments – despite best intentions, aspects of the 
treatments can break the blind. If we consider for example antipsychotic medication, it is 
clear that an allegedly double blind trial would be almost impossible to achieve, since there is 
compelling evidence regarding the rapidly observable adverse effects of both first and second 
generation antipsychotics (e.g., rapid and dramatic weight gain and parkinsonian side 
effects), which may result in clinicians and raters being unblinded. Another possibility is that 
subjective cognitive effects208 may be likely to unblind participants.  
A set of reporting standards that are specifically tailored to psychological therapy 
trials are being developed as an extension of the original CONSORT guidelines209. These 
include recommendations to improve internal and external validity, address measurement 
issues (psychological therapy trials often have many measures, many of which assess latent 
constructs), improve reporting of recruitment processes and representativeness of participant 
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samples and increase contextual information such as factors that helped or hindered the 
interventions. More broadly, further research on trials methodology (for example, on how to 
deal with the issue of blindness) will be an important area of future enquiry.  
 
Reducing conflicts of interest 
Some have argued that the conduct of a clinical trial by the developer of a 
psychological therapy is equivalent in terms of bias to industry-sponsored trials. In accord, 
investigator allegiance effects have been observed in psychological therapy trials210, 211. On 
the other hand, the level of independent scrutiny from peer review by methodological experts 
and the obstacles to obtaining funding to conduct the trial are likely to be greater for 
psychological therapies than for industry-sponsored pharmaceutical trials, since 
psychological therapy trials are usually publicly funded by research councils or national 
institutes. That is, although trials of psychological therapies may be conceived and conducted 
by the originator, they are rarely funded by the originator. Nonetheless, steps can be taken to 
reduce bias. These include a declaration of interests (personal financial interests such as 
training fees, book royalties and non-financial interests). The registration of protocols, pre-
specification of statistical analysis plans, and involvement of independent methodologists in 
trial design and data analysis would also mitigate against such bias. Trial Steering 
Committees and Data Monitoring Committees with independent clinical, statistical and 
service user representation also increase confidence and minimise bias. These committees can 
provide constructive criticism and protect the safety of participants and the scientific integrity 
of the trial. Expertise in all relevant approaches is important for trials that compare two or 
more therapies; for example, the COMPARE trial team includes expertise in both CBT and 
antipsychotic medication. 
 
Inclusion and exclusion criteria 
The selection and justification of inclusion and exclusion criteria are vital to good trial 
design. They should be specific enough to allow the identification of suitable participants and 
replication of a trial, but broad enough to reflect real world clinical settings and permit 
generalisability, according to the purpose of the trial. Historically, many psychological 
therapy trials require a single diagnostic category or symptom as entry criteria, not allowing 
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several or at least specific comorbid conditions (e.g., other mental health problems, physical 
health issues, drug or alcohol use). This is difficult to justify when the clinical reality is one 
of complexity, with comorbidity being the norm (see also section 8 Complexity). More recent 
trials that have evaluated CBT for psychosis have, in general, been good in terms of 
generalisability, allowing for inclusion of participants who meet such broad criteria (this is 
also true for trials of psychological therapy for depression212). Even trials that have focused 
on mechanisms of change, such as whether reducing worry processes results in reduction in 
paranoid thinking, have allowed significant comorbidities213. However, there may be a trade-
off between clinical pragmatism (broad entry criteria) and the ability to scrutinise specific 
mechanisms within a trial. One exception to this is trials that attempt to address 
transdiagnostic processes by targeting a specific mechanism, such as modification of 
attentional biases or extended perseverative processing, or a specific problem, such as sleep 
difficulties or irritability, across diagnostic groups. This approach offers potential advantages 
in terms of recruitment, generalisability and implementation in services (see Section 8 
Complexity, for further discussion of these issues).    
Better integration of research trials within clinical settings would also allow 
improvements in the generalisability of results to the real world. One goal is for every 
individual who attends a hospital clinic, engages with a community mental health team or 
attends an appointment in primary care to be offered participation in psychological therapy 
research (if willing and able to provide consent). For example, in cases in which there are 
genuine uncertainties (e.g., what ‘dose’ of CBT for psychosis is required), all willing 
participants could be randomised to different treatment duration options (e.g., up to 16 or 32 
sessions). 
 
Choice of control condition 
There is considerable debate about appropriate control conditions; for example, many 
argue that “treatment as usual (TAU)” is not appropriate since it may be highly variable and 
at times include access to the treatment being provided in the experimental arm. The use of 
an active control condition, which reduces confounds of nonspecific factors such as attention, 
warmth, human relationships etc. is often recommended; however, this may oversimplify the 
issue of therapeutic relationship – itself a topic of research enquiry and debate about its 
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importance. The provision of an alternative therapy can raise other confounds such as the 
‘match’ between therapist and participant and the ability of a therapist to switch between, and 
adhere to, different treatment protocols when it is likely they have greater skill and allegiance 
in relation to one or the other. There are ways to deal with such issues – for example, multiple 
therapists providing each active treatment condition. Indeed, numerous trials have succeeded 
in using therapists from both background treatments (e.g., CBT and psychodynamic) who 
deliver both treatments. Nonetheless, there are many issues that arise in conducting trials 
which continue to require thought. For example, in a trial in which CBT for psychosis was 
compared with befriending, the befriending condition was delivered by trained cognitive 
therapists214. This could be problematic for a number of reasons, including the possibility that 
the trained cognitive therapists had significantly better therapeutic skills and training, or were 
biased because they are not allegiant to this approach. Most studies have tried to ensure that 
expert therapists deliver both treatment modalities (e.g.,215,216), such that different trial sites 
have different expertise/allegiance, but deliver all therapies. Furthermore, there may be 
differences between conditions in the effectiveness of psychological placebos. For instance, 
the effects of non-directive supportive therapy are comparable to CBT and interpersonal 
psychotherapy for depression217, although CBT is superior in the case of psychosis218 and 
anxiety disorders.  
Clinical psychological trial experts such as Kazdin have formulated models to help to 
guide the type of trial needed to address the type of question asked – and this is a ripe area for 
continued methodological development. Design solutions will depend, in part, on the specific 
research question; for example, if the pragmatic question is whether something works better 
than current provision, then a two-arm trial for comparison against a specified and 
protocolised treatment as usual that utilises best current practice may be ideal (for example, 
CBT plus monthly engagement and monitoring of current difficulties compared to monthly 
engagement and monitoring alone219). If the question is whether one form of psychotherapy is 
better than another, then a head to head comparison may be required (for example, if CBT 
was to be compared to acceptance and commitment therapy, which has recently been 
suggested as an alternative to CBT). If the question is why a treatment works or whether a 
specific element is necessary, then a therapy which controls for specified factors (such as 
human contact) but in which the active ingredient has been removed may be indicated (for 
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example, CBT compared to befriending for people with psychosis214). Meta-analyses would 
suggest that waiting list controls should probably be avoided, since they can lead to inflated 
effects sizes for the experimental treatment, possibly by leading people to abandon efforts to 
solve problems or recover independently because they are waiting for therapy43. 
 
Outcome measures 
Most trial methodologists would recommend a single primary outcome and a single 
time point (e.g., total symptoms at final follow-up assessment) which can sit uncomfortably 
with basic aspects of psychological assessment – such as the need for multiple assessments of 
a construct for validity and multiple time points for reliability. However, there may be times 
when more than one primary outcome is justified (e.g., if there is considerable disagreement 
between stakeholders, such as clinicians and service users), although it is important to note 
that multiple primary outcomes have consequences for power calculations, requiring larger 
sample sizes. In addition, maximising the use of data obtained at multiple time-points in order 
to obtain the most accurate estimate of treatment effects over the full follow-up duration can 
be achieved by specifying an analysis involving all available data for a particular measure, 
which may be preferable to anchoring judgements regarding efficacy to a single assessment 
point. 
There is often debate about which is the most important outcome. For people with 
psychosis, there is debate regarding whether clinical outcomes (e.g., psychiatric symptoms) 
or social outcomes (e.g., recovery, social functioning and quality of life) are the most 
important. The answer to this question largely depends upon who is asked, such that 
clinicians often prefer the former and service users prefer the latter220. In the COMPARE 
trial, being a feasibility trial, all of the above are included and all participants are asked to 
rank the outcome measures in order of importance to them in order to inform a subsequent 
definitive trial. A definitive trial could require two primary outcomes: a measure of 
psychiatric symptoms (e.g., PANSS total), which would allow clinicians to judge findings in 
relation to the existing literature, and a measure of self-judged recovery or objective quality 
of life which would allow service users to make informed choices on the basis of their own 
priorities. Reliance on subjective measures alone can be a limitation - convergent objective 
outcomes such as behavioural, cognitive or physiological or neural response to specific 
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stimuli may bring methodological advantages (see also Section 5, Technology and Section 1 
Mechanisms).  
 Consensus regarding outcome measures for a specific condition would also enable 
large “individual participant data” meta-analyses221-223, which can hopefully inform the 
moderators and mediators of treatment response (i.e., what works for whom; see also Section 
8, Complexities), and integration with and adoption of routinely collected service outcome 
data would also help facilitate this. There is a UK initiative that aims to establish agreement 
about core outcome sets for particular health conditions (COMET: http://www.comet-
initiative.org/about/overview); there is work underway to establish consensus about a core 
outcome set for evaluations of interventions for people with psychosis224. It is unclear 
whether a detailed interviewer administered rating scale, which may provide rich data and be 
more engaging for participants, or a self-report measure, which may be more reliable (since 
there is no need for inter-rater reliability across sites and staff) and avoids rater bias, are 
preferable. Again, a combination of both, so long as they are clearly pre-specified as dual 
primary outcomes, could represent a reasonable solution that maximises the benefits of both 
approaches; if a trial with dual primary outcomes demonstrated consistency across them, then 
this would increase confidence in findings. 
Another important consideration when selecting outcomes is the length of the overall 
battery of assessments. Psychological therapy trials are notorious for the inclusion of 
numerous secondary outcome measures, which may be of significant interest. However, the 
greater the assessment burden on participants, the more likely it is to affect retention in the 
trial and subsequently result in missing data in the outcomes. Limiting the selection of 
outcome measures is likely to minimise attrition. T this is extremely important since high 
levels of attrition represents a significant threat to the internal validity of the trial (although 
we acknowledge that limiting measurement also limits opportunities for understanding 
processes of change). Similarly, agreement regarding the frequency of assessment occasions 
and length of follow-up would help to minimise attrition and also facilitate the pooling of 
data and the capacity for comparisons across trials. However, there is a trade-off between 
collecting meaningful data that will permit identification of what works for whom across a 
broad range of outcomes and facilitate mediation and moderation analyses, and ensuring that 
participant retention is not jeopardised. The involvement of service users who would be 
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eligible for trial participation in trial design, as well as ensuring pilot and feasibility work has 
been done, are both likely to be useful strategies in achieving this balance. Another 
possibility for minimising burden and maximising both ecological validity and multiple 
measurements of outcomes is to use Experience Sampling Method (ESM) or Ecological 
Momentary Assessment data as outcomes. This would allow reporting of symptoms, 
emotions and indicators of functioning, such as time use in daily life as primary outcomes in 
clinical trials (see section 8 Complexity for further discussion of ESM).In addition to the 
measurement of wanted effects, such as improvement in symptoms or quality of life, it is also 
important to measure unwanted effects and report serious adverse events (SAEs) that are 
reported to ethics committees as part of safety monitoring. Historically, trials of 
psychological therapies have been poor at both monitoring hypothesised side effects and 
deterioration and reporting SAEs207. Several recent trials of CBT for psychosis have 
attempted to measure adverse effects via qualitative and quantitative approaches. There have 
been suggestions that CBT for psychosis may be associated with increasing stigma, 
encouraging deterioration or destabilisation or leading to SAEs such as hospitalisation. 
However, the trials that have measured this have demonstrated the opposite when compared 
to control conditions219,225. This is especially surprising when the inbuilt detection bias is 
taken into account (therapists may have weekly contact with a participant, whereas raters may 
only have contact at baseline, end of treatment and follow-up, which clearly reduces the 
likelihood of detection of SAEs). 
 
Public and patient involvement 
Public and patient involvement226, 227 is another area that can help to improve the 
conduct of psychological therapy trials. People with mental health difficulties can obviously 
provide unique insights into to improve clinical trials, including identification of the most 
important and relevant research questions, possibly via consultancy groups (which was the 
case for the COMPARE trial), via priority setting partnerships (PSPs) that identify and 
prioritise the top ten unanswered questions (the James Lind Alliance facilitate the 
development of PSPs; see http://www.jla.nihr.ac.uk/ ), which has been done for the treatment 
uncertainties related to a diagnosis of schizophrenia228, or by the use of Delphi methods to 
establish consensus on topics with experts by experience (the COMPARE trial was also 
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informed by Delphi studies of people with psychosis on both defining recovery229 and 
identifying treatment priorities and preferences230). 
The choice of research question via public/patient involvement is crucial to 
subsequent trial design. For example, a definitive trial of CBT compared with antipsychotics 
would need to decide whether the most important question is one of superiority (e.g., is 
combined therapy superior to monotherapies), one of equivalence (which would enable 
choice) or non-inferiority (which may indicate one treatment or another given the differences 
in adverse effect profiles, although this will always be dependent on individual choice, since 
what is an acceptable side effect will vary considerably between people). Public and patient 
involvement can also help with the selection of appropriate outcome measures and decisions 
about what should be primary versus secondary outcomes, as described above. In addition, 
the assessment of acceptability of psychological therapies, as well as exploration of potential 
adverse effects, can be helpfully informed by embedded qualitative interviews and analyses 
that can be user-led (again, the COMPARE trial incorporates such a study). Finally, the 
involvement of service users as staff and, ideally, co-applicants and investigators, should 
ensure meaningful participation in all phases of trial design, conduct and reporting 
(COMPARE has two service user co-investigators/grant holders).  
 
Mechanisms and mediators of change 
Trial design should also attempt to facilitate the identification of potential 
mechanisms and mediators of change (see Section 1, Mechanisms), as well as moderators of 
treatment effects - in order to inform how a treatment works, what components are necessary 
and sufficient and what works for whom. This approach will help to improve and refine 
treatments, make them more efficient and permit true informed choice for service users and 
carers. The identification of mechanisms could be built into all clinical trials, which would 
allow pooling of data, although this would also require some consensus among researchers 
about the instruments that should be included in the trials. When a specific research question 
involves testing a mechanism, the trial must have sufficient statistical power for the 
mechanistic hypotheses as well as any between-group predictions. 
The identification of mediators and moderators also requires considerable thought at 
the planning stage to ensure that the appropriate factors are measured at the appropriate time 
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points. The development of new statistical methods for the analysis of mediation and 
moderation should also help with the accurate identification of mechanisms of change and 
mediators of treatment outcome. Traditional approaches to mediation analysis231 assume that 
confounding due to an unmeasured variable being responsible for changes in both mechanism 
and outcome is absent, which is problematic. More recent developments, such as attempting 
to measure and adjust for all important confounders232 or attempting to effectively adjust for 
unmeasured confounders (hidden confounding) using instrumental variable-based methods 
employing analyses based on principal stratification233 provide statistical tools that may be 
better suited to this purpose. Recent examples relevant to CBT for psychosis include the 
finding that participants with a psychosocial causal explanation of their difficulties may be 
more likely to engage with and benefit from CBT234 and that participants with a good 
therapeutic alliance with their therapist are likely to benefit from a higher number of CBT 
sessions, whereas those with a poor alliance may be more likely to experience harm from a 
higher number of session235. See also Section 8, Complexity for a related discussion regarding 
personalization. 
 
Innovation in trial design and methodology 
The wider context surrounding an individual trial is important to consider. The design 
of clinical trials by consideration of the factors outlined above should facilitate the 
subsequent pooling of data (e.g., standard approaches to outcome and mechanism 
measurement, timing of assessments, length of follow-up, treatments that are well 
operationalised, inclusion and exclusion criteria that reflect real-world populations). If 
consensus regarding such issues can be obtained, this would permit meta-analytic approaches 
that could represent a sensible long-term approach to provision of definitive answers to 
important research questions. The reliability and validity of the findings from meta-analyses 
that are used to inform policy, guidelines and service recommendations are largely dependent 
upon the quality of the trials that are included and the suitability of the selection criteria (i.e., 
whether the included trials were designed to answer equivalent questions). Therefore, 
designing high quality trials with a view to the longer term perspective could provide an 
opportunity to help such meta-analyses benefit from better trials suitable for this purpose. 
Collaboration between research groups, investigators and methodologists with regard to 
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future pooling of data could be facilitated by the establishment of collective research groups 
recognised by group authorship, which would incentivise such involvement and co-operation. 
There is currently such an initiative in attempting to pool data from all CBT for psychosis 
trials in order to conduct an individual level data meta-analysis that will attempt to examine 
individual moderators of treatment response. 
At times, there is a need for alternative approaches to the traditional two-arm 
randomised controlled trial, such as multi-arm multi-stage trials236. The two-arm RCT has 
been adopted as the gold standard from methods used to evaluate pharmacological 
interventions (mostly industry sponsored drug trials). However, many of the lessons learnt on 
the basis of such drug trials are applicable to improving the reliability and validity of research 
to evaluate psychological therapies, including the need to minimise bias by avoiding selective 
reporting, maintaining blinding, independence of randomisation, minimising attrition, 
appropriate selection of participants and comparators and reporting in line with CONSORT 
recommendations237, 238.  
The use and further development of new methodologies including adaptive designs, 
preference trials, and sequential, multiple assignment, randomised trials (SMART trials) 
should facilitate trials that are fit for purpose to answer important questions. Such 
methodologies will permit better generalisability to routine practice and more ethical and 
efficient trial conduct. For example, a SMART permitting re-randomisation for non-
responders to CBT or antipsychotics to the other monotherapy or the combination, after a 
relatively short period of time, would confer advantages; a preference trial would maximise 
recruitment in a field in which both service users and clinicians may have strong treatment 
preferences and opinions about talking therapy and/or medication that would jeopardise 
recruitment, generalisability and/or adherence to allocation in a standard RCT; an adaptive 
design with a planned and pre-specified interim analysis may permit the early abandonment 
of an arm that may be inferior. Again, the linkage between experts in trial design and 
analysis, experts in the development of psychological therapies and experts by lived 
experience will be central to making such progress. Another development that could 
maximise both availability of trial participation for service users and utilisation of research 
opportunities to inform clinical practice and policy making is the “cohort multiple 
randomised controlled trial” design239. This approach allows several RCTs to be conducted 
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simultaneously within a larger cohort or register of patients. For each RCT, all eligible people 
in the cohort are identified, and then some are randomly selected to be offered the 
experimental trial intervention. The outcomes in the randomly selected participants are then 
compared with the outcomes in those who were eligible but not selected (i.e. receiving 
standard care or treatment as usual). Such designs could overcome recruitment difficulties, 
and increase statistical power, efficiency, representativeness of samples and comparability 
between trials, as well as increasing knowledge about the natural course of mental health 
problems and the likelihood of collecting data on long term outcomes. This approach would 
be ideally suited to mental health problems that are seen within specialist teams (e.g. eating 
disorders or first episode psychosis), especially when the teams are linked within a national 
or international network and routinely monitor outcomes in a standardised way. Trials within 
cohorts could be the ideal solution to making the most of opportunities to utilise large data 
sets of routinely collected outcomes while still retaining randomisation as the cornerstone of 
trial methodology and statistical analyses.      
Finally, it is important to recognise that research to identify successful interventions is 
not just about RCTs (the seminal BMJ paper240 demonstrating the lack of trial evidence for 
parachutes illustrates this perfectly), and clinical trials should complement other types of 
research questions and evidence. An example of this is the need for RCTs to include 
embedded qualitative studies that seek to obtain rich data that will allow triangulation with 
quantitative outcomes as well as inform our understanding of active treatment processes and 
the generation of new hypotheses to test empirically. For example, the COMPARE trial 
involves interviewing participants about their experiences of both CBT and medication, 
focusing on acceptability, credibility and wanted and unwanted effects (these interviews are 
designed, conducted and analysed by researchers with lived experience of psychosis), which 
has the potential to inform the design of a definitive trial in relation to selection and 
recruitment of participants, entry and exclusion criteria, outcome measures and treatment 
protocols.   
Conclusion 
If all of the above can be achieved, this will increase our ability to identify and answer 
the most important questions, conduct trials with greater reliability and validity and, 
therefore, increase the confidence in and acceptance of their findings (see Panel 15). In 
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particular, developments in three areas could dramatically improve trial quality in the 
evaluation of psychological therapies. An ability to better detect responders and non-
responders would allow us to identify what works for whom (see Section 8, Complexity); this 
could be achieved by ensuring better selection of measures, incorporation of experience 
sampling or momentary assessment in the early phases of a trial (see Section 5, Technology), 
use of improved inclusion and exclusion criteria and the development of statistical methods 
for mediation, moderation and consideration of individual response trajectories rather than 
aggregate effects. Meaningful involvement of service users and carers will allow us to 
identify the appropriate research questions and methods, ensure relevance of outcomes 
(including adverse effects) and improve retention of participants. Finally, facilitation of large 
scale data sets, whether by consensus regarding design considerations and measures that 
enable pooling of data, developments in individual participant data meta-analyses or the use 
of routinely collected service data, will promote confidence in the results of our clinical trials. 
 
Panel 15. Directions and Priorities for Future Research in Clinical Trials of 
Psychological Treatments 
 We need to establish consensus amongst stakeholders (the innovators and 
developers of psychological treatments, service users and methodologists) 
regarding outcome measures, appropriate scheduling of assessments and length of 
follow-ups 
 We need to routinely build into the design of clinical trials the ability to analyse for 
mechanisms (see section 1 Mechanisms) 
 We need to engage with commissioners and providers of psychological services to 
maximize the likelihood that such services can facilitate the collection of data and 
build in trials where there is uncertainty 
 We need to ensure quality trial design and valid, reliable analysis of data by routine, 
early engagement with Clinical Trials Units, trails registration for all trials 
including production of pre-specified Statistical Analysis Plans, and ensure that 
data analysis adheres to such plans and is conducted by independent specialists in 
trial statistics 
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 We need to involve service users in all aspects of trial design and conduct, from 
decisions regarding research questions and methods, through to involvement in trial 
management and governance, research administration and interpretation and 
dissemination of findings 
 We need to carefully match comparators to the specific research questions that 
trials are seeking to answer 
 We need to measure unwanted effects as well as wanted effects, and arrive at a 
consensus about how to measure and report adverse effects 
 We need to increase our use of innovative trial designs that maximize value for 
money, value for participant input and reflect clinical practice; such designs include 
adaptive trials, multiple trials within cohorts, SMART trials and preference trials. 
Different designs will be suited to different research questions and clinical contexts 
 We  need to encourage career paths for those focussed on advancing methods in 
psychological treatment trial design methodology, statistics and so forth 
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7. Training: Can we foster a vision for interdisciplinary training across mental health 
sciences to improve psychological treatments? 
 
Overview: Training 
In this section we discuss why we should endeavour to improve the links between 
clinical psychology, psychiatry and basic research training, and make some proposals about 
how this might be achieved. We review some early successes in innovation in psychological 
treatments when basic researchers and clinicians have worked together, and discuss the 
reasons that such fruitful interaction has decreased in recent years. We offer some concrete 
recommendations to bridge the gap between clinical practice and basic research relating to 
psychological interventions. 
 
Historical shifts in interdisciplinary training 
In 1949 the American Psychological Association convened the famous Boulder 
(Colorado) Conference on Graduate Education in Clinical Psychology, in order to agree on a 
standard model for clinical psychology training in the US. Heavily influenced by the ideas of 
David Shakow, it adopted a “scientist-practitioner” training framework that encouraged 
clinical psychologists to use scientific research to inform their treatment241. This influential 
proposal facilitated the development of effective new psychological interventions, which was 
catalysed by clinicians who performed basic research, and basic researchers who understood 
the principles of psychological treatments (see Panel 16). This confluence of expertise 
resulted in vital insights into the mechanisms of onset, maintenance and treatment of 
symptoms of mental health problems, and in some case completely revolutionised the 
psychological treatments available.  
For example, the development of various types of exposure therapy (incorporating 
response prevention) for anxiety disorders, including phobias, PTSD and OCD, was initially 
derived from fear extinction research in rodents, which showed a reduction in Pavlovian 
responses to negatively conditioned stimuli when the aversive outcome was omitted242, 243 
(see also Section 1, Mechanisms). Importantly, the focus on response prevention, i.e., 
encouraging patients suffering from anxiety not to engage in their usual coping strategies 
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when confronted with an anxiety-provoking stimulus (for example, avoidance for phobias or 
rituals for OCD), came from the insight that these behaviours can maintain the conditioned 
association through preventing extinction244. This might appear counterintuitive to the patient 
because, acutely, the prevention of coping behaviours increases anxiety in the short-term, but 
leads to a reduction in anxiety in the long-term.  
In depression, the influential “learned helplessness” model245, and its later 
modifications in relation to hopelessness246, originated from the finding that animals exposed 
to inescapable aversive stimuli subsequently failed to escape when they had the option to do 
so247. Learned helplessness theory made important contributions to our understanding of risk 
factors for depression, especially relating to the roles of attributional style and perceived 
controllability248. Moreover, it inspired numerous animal models that remain the mainstay of 
testing procedures for new antidepressant drugs in preclinical research, and translational 
research in this field has yielded valuable insights into the basic cognitive and brain changes 
that underlie depressive symptoms and their response to treatment249. 
 
Panel 16. What Types of Backgrounds do Clinicians and Scientists 
in Psychological Treatment Research Have? 
 Clinical psychologist: Psychological therapist, holding an advanced qualification 
such as a doctorate (e.g. in the UK DClinPsy, in the USA/Canada PhD or PsyD) or 
Masters (in most other countries), and usually also an undergraduate qualification 
in psychology; trained in interventions that relieve psychological distress 
 Psychiatrist: Medically qualified doctor who focuses on treating mental health 
problems; can legally prescribe medication, but may also be trained in delivering 
psychological interventions 
 Basic researcher: Usually a university academic holding a PhD, who conducts 
research in areas including (but not limited to): experimental psychology, clinical 
psychology, neuroscience, genetics, physiology, pharmacology, data science, social 
science, economics 
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 Clinician scientist / Scientist practitioner: Psychiatrist, clinical psychologist or other 
mental health practitioner who is also trained in research, often having obtained a 
PhD 
 
Over the past several decades the links between basic research, clinical psychology 
and psychiatry have become increasingly weak. There may be multiple reasons for this. One 
simple fact is that due to the rapid expansion of psychology, psychological treatment 
researchers and practitioners rarely sit in the same building as, for example, social scientists, 
economists, neuroscientists or geneticists. This reduces the opportunity to both interact and 
share ideas, and critically stops potential insights whereby either side can see what they may 
be missing. Another important issue is that basic researchers and clinical psychologists often 
do not read the same journals, or even attend the same conferences, meaning that 
opportunities for interaction are limited2. 
 
Renewing the links between basic research and psychological treatments 
Clinicians providing psychological treatments need training in basic research. In 
most countries, there is relatively little teaching of contemporary basic research (for example, 
experimental psychology, neuroscience, genetics, physiology, pharmacology, data science, 
social science, economics) incorporated into the clinical syllabuses in the disciplines of either 
clinical psychology or psychiatry, or in that of allied professional training in mental health 
treatment. The US and Canada are notable exceptions, where many clinical psychologists 
complete a doctoral training programme of at least 5 years’ duration, which includes 
substantial basic research teaching together with an extensive research-based thesis, as well 
as clinical training. The basic science content provided to psychiatry trainees in the US has 
also increased in recent decades250, although there is recognition within the profession that 
further such training would be desirable251 (see also the report of the UK Academy of 
Medical Sciences (2013), "Strengthening academic psychiatry in the UK"). Other than these 
examples, the basic research content included even in doctoral-level clinical psychology 
programmes (e.g., PsyD in the US/Canada, which is taken by approximately half of all 
qualified clinical psychologists in these countries; DClinPsy in the UK) is limited. And in 
other countries, where a Masters degree is the standard educational qualification required to 
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become a clinical psychologist (including most of the EU, Australia, New Zealand and South 
Africa), there is very little basic research content in the curriculum. 
This raises a serious concern about the training of clinical mental health researchers of 
the future. In particular, there is a risk that they will not be equipped with the tools to 
understand, critically evaluate and utilise basic research that might be relevant to the 
development of new treatments or preventative strategies. A corollary to this is that there is a 
danger that psychological interventions may become “stuck in the past” – relying on outdated 
models that are not supported by contemporary research or theory. This disconnect hinders 
innovation, and the slow emergence of effective, truly novel psychological treatments in part 
attests to this. Unless clinical psychologists and psychiatrists are equipped with the skills to 
evaluate research on both risk factors (for example, genetic and socioeconomic influences) 
and proximal mechanisms (for example, cognitive and neural processing of information), it is 
difficult to know where to start thinking about improving preventative strategies and 
treatments. However, it is also important to bear in mind that learning about a technique may 
be forgotten if it is not put to use.  
Basic researchers need training in clinical conditions and psychological treatments. 
From the perspective of basic researchers, despite enthusiasm for the notion that their 
research might contribute to improved mental health treatments, most have a very vague 
conception of what standard psychological interventions entail, as clinical practice is not 
generally taught even in undergraduate level psychology degrees. Specifically, many basic 
researchers have little knowledge of the evidence base supporting standard psychological 
treatments, and have little opportunity to interact with clinical psychologists, to see therapy in 
action, or to find out what the common techniques comprise. Indeed, the view that 
psychological treatments are primarily delivered in the context of an anti-empirical 
psychoanalytic couch tradition, and that they are not derived from solid scientific theory or 
supported by robust evidence from clinical trials, is worryingly prevalent among basic 
researchers in our experience2. In order to be able to formulate relevant research questions, 
basic researchers who are interested in contributing to the development of psychological 
treatments need to understand, at least at a basic level, what the symptoms of mental health 
problems are (and are not), what the most commonly used and evidence-based psychological 
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interventions entail and how theoretical models guided their development, and which are the 
key questions to solve (and which are not) for the future.   
 
Panel 17. An Example of How Neuroscience Might Inform Psychological Intervention 
Development: Could Understanding Reward Processing in the Brain Help in the 
Development of New Treatments for Anhedonia? 
 Over the past decade there has been renewed interest in a core symptom of 
depression, anhedonia, which is the loss of interest or pleasure in previously 
enjoyable activities. Anhedonia is also an important component of many other 
mental health conditions including schizophrenia and addiction, as well as being a 
prominent symptom in neurological disorders such as Parkinson’s disease. In 
depression, anhedonia is associated with a more severe course of illness and poor 
response to standard antidepressant drug treatment252. 
 Given that anhedonia is intrinsically related to an absence of motivation and 
hedonic response, it has been proposed that this symptom may arise due to 
disruption of the brain’s reward circuits253, which have been characterised in 
extensive detail by neuroscience research over the past 30 years. This is not a new 
idea – in the 1970s Jeffrey Gray first proposed that symptoms of depression might 
be explained by changes in a “Behavioural Activation System” (BAS) and a 
“Behavioural Inhibition System” (BIS)254, although most depression researchers 
focused on the BIS and its relationship with neuroticism. However, an important 
conceptual advance since that time has been the notion that the reward system 
(BAS) comprises several relevant cognitive processes: hedonic response to reward 
delivery, valuation of rewards, reward learning, propensity to exert effort and 
decision-making. These components at least partially dissociate, and are associated 
with activation in different brain circuits and different neurochemical systems255. 
 
 This knowledge from neuroscience research has been exploited by clinical 
psychologists seeking to develop treatments specifically targeted at anhedonia, for 
example Positive Affect Treatment (PAT)255. This builds on Behavioural Activation 
therapy and Positive Event Scheduling, both effective treatments for depression256 
 
 
90 
 
 
that were originally motivated by ideas derived from behaviourism40, and that are 
known to increase responsivity in the brain’s reward system257. Drawing on the 
finding that reward processing comprises a diverse set of processes, the aim of the 
PAT package is to increase engagement in, attention to and anticipation of 
enjoyable activities16. Coming from a complementary angle, another novel 
approach based on cognitive science (here, the processes of mental imagery and 
interpretation bias) has been to use positive imagery training, which in trials has 
shown some effect in depressed individuals suffering from anhedonia258, 259. This 
focussed approach has been incoporated into the wider PAT package. While these 
novel interventions require further evaluation specifically in groups of anhedonic 
individuals, they provide examples of how scientific discoveries are being used to 
develop innovative psychological interventions. 
 
The future of interdisciplinary training 
Training clinicians in basic research. How can we ensure that the next generation of 
research leaders, both clinical and basic, is able to bridge this growing divide? One priority is 
to provide more academic training opportunities for trainees and qualified practitioners, and 
to attract those with a strong aptitude for research. It is notable in the UK that although 
competition for places on clinical psychology professional doctorate courses is intense, and 
these recruit highly academically able students, very few subsequently develop a clinical 
research career. Funding opportunities for academic training of qualified clinical 
psychologists are highly competitive. That said, major UK research funding bodies, such as 
the National Institute for Health Research (NIHR) and Medical Research Council (MRC), 
offer academic training pathways for clinicians. These offer clinically-qualified, non-medical 
healthcare professionals the chance to undertake a PhD, whilst covering a clinical-level 
salary, as well as tuition, travel and training costs, and research consumables footnote #3. This 
provides a valuable springboard for a clinical research career, but there is much greater scope 
                                                          
footnote #3: MRC: http://www.mrc.ac.uk/skills-careers/fellowships/clinical-
fellowships/clinical-research-training-fellowship-crtf/ NIHR: 
http://www.nihr.ac.uk/funding/nihr-hee-ica-programme-CDRF.htm 
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for uptake by clinical psychologists, in part because they may not be aware of these 
opportunities or have sufficient support or research experience to develop a strong 
application. Another way of improving academic training in clinical psychology would be to 
create longer training programmes specifically for those trainees with a strong aptitude for 
research, similar to the North American PhD model, which would provide sufficient time to 
conduct an extensive research project as well as teaching relevant scientific material 
alongside clinical skills. The PCSAS model recently developed in the US, which emphasizes 
the science of clinical psychology in training and internships, would also be an effective way 
of increasing research training opportunities. Another similar training model exists in 
Australia, in which students are enrolled in a clinical training program and PhD program 
concurrently – and are awarded both degrees at the conclusion (e.g., Master of Psychology 
(Clinical) / PhD). This ‘combined’ degree is offered at The University of New South Wales 
(UNSW Sydney). 
We also need to develop training pathways for mental health researchers that foster an 
interdisciplinary approach, both between clinical psychology and psychiatry, and between 
clinical mental health disciplines and a variety of relevant basic research disciplines. One 
possibility would be to encourage clinical psychologists to undertake internships or 
placements in basic research settings across a range of relevant disciplines, from economics 
and social science to neuroscience and genetics. Psychiatrists in the UK already have such an 
opportunity through the NIHR Clinical Academic Fellowships scheme, but we are aware of 
no equivalent programme for clinical psychologists, in either the UK or other European 
countries. Multi-skilled clinical academics, trained in an interdisciplinary environment, would 
have the advantage of being able to ‘speak the languages’ of both clinical and basic research. 
They would also be best placed to develop the meta-professional skills needed to conduct 
truly interdisciplinary translational research, and to use the knowledge derived from basic 
research to drive innovation in psychological treatment development. 
Training basic researchers in psychological interventions. Basic researchers with an 
interest in understanding and contributing to the development of new psychological 
treatments need to be provided with the opportunities to do so. In the same way that a first 
year neuroscience PhD student might learn about the principles and practice of neuroimaging 
analysis, and therefore be able to evaluate neuroimaging evidence more effectively because 
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they understand the potential pitfalls (even though they may never use this technique), basic 
researchers need a route through which they can learn about what psychological treatments 
are and how they are theorised to work. This would provide a new generation of researchers 
who understand the basic principles underlying psychological interventions and could bring a 
fresh perspective on driving innovation. Simply sitting in the same lectures and tutorials as 
clinical trainees would increase the opportunity for meaningful interaction, and encourage 
both clinical and non-clinical students to value input from the other in developing 
collaborations. While neuroscience and cognitive/experimental psychology students are 
obvious candidates here, students with backgrounds in a whole range of disciplines, from 
social science and economics, to computer science and mathematics, through to molecular 
biology and genetics, may have an interest in psychological interventions and be able to 
contribute important ideas. 
Training the culture to accept more crossover. At present there are structural 
obstacles to addressing the problems mentioned above that require bold changes in thinking 
to overcome. These obstacles are present both in terms of clinical accreditation and funding. 
There is a huge amount of research talent among mental health practitioners that is under-
utilised, and perverse incentives, including a possible reduction in salary and a perception 
that research will not help career progression, often discourage clinicians from entering 
academia. Importantly, the majority of clinical psychologists and psychiatrists never have the 
opportunity to gain a rigorous training in basic research, and almost never train alongside 
each other. Additionally, the procedures for obtaining funding for a research doctorate are not 
widely understood among trainees, and the opportunities to gain the research experience that 
would contribute to a competitive application are sporadic and invariably depend on locally 
available supervisors, meaning that the trainees with the most research potential may be 
overlooked. Finally, unlike for clinical training (at least in the UK), there is a lack of national 
recruitment for research training in clinical psychology. These obstacles could be addressed 
through targeted, longer programmes (similar to the PhD pathway in North America) that 
include a considerably more substantial research component to the professional doctorate 
(alongside standard clinical training), and recruit nationally in order to attract the trainees 
with the greatest research potential. More substantial research projects would also help to 
address the concern that learning about techniques may be forgotten if not put into practice. It 
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should be noted that many European clinical psychology training programmes do 
successfully blend clinical training with basic research – although the relatively short periods 
of these Masters level programmes and lack of requirement for a doctoral level thesis mean 
that trainees do not receive the same level of research training as in the North American PhD 
model. For example, an interesting model of training clinical psychologists in recent years 
has been pioneered by Karolinska Institutet (Sweden). In this model, clinical education is 
based within the Department of Clinical Neuroscience, and within a medical university. This 
has resulted in high level of exposure to both psychology and neuroscience, as well as 
encouraged awareness of the rich links to physical medicine. Almost all the instructors are 
involved in research, and a majority have at least 50% of their time devoted to research. 
Although only a Masters level qualification is required to become a clinical psychologist in 
Sweden, Karolinska students are poised as a new generation of scientist-practitioners - 
although naturally not at the same level as students who have completed a longer doctoral 
level programmes in North America. The development of similar programmes elsewhere 
would be a positive step, as would an examination of the outcomes of different international 
models. To our knowledge, such an investigation has not been conducted to date, but would 
be extremely valuable.  
Models of shared research supervision. Another major limiting factor is that those 
who do enter research training are often only supervised by clinicians, rather than by basic 
researchers. This divide cuts both ways – as discussed above, there are likewise very few 
opportunities for basic research trainees who are keen to understand psychological 
treatments, and to find out what they entail, and the diverse approaches that they adopt. Such 
exposure to ideas, and understanding how psychological interventions are actually conducted, 
is an important first step for basic researchers to start to formulate valuable research 
questions. It would therefore be desirable, where possible, for basic researchers to play a 
more active role in the supervision of research projects of clinical psychology trainees, and 
vice versa. Encouraging joint doctoral supervision (whether for research or clinical students) 
between basic researchers and clinical psychologist PIs would be a simple and valuable step 
in the right direction in this regard. Returning to our Australian example above, at UNSW 
Sydney, combined clinical / PhD students often conduct their PhD research under the 
supervision of basic researchers (e.g., behavioural neuroscientists) and test questions with 
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clear clinical relevance (e.g., on topics such as fear extinction, drug addiction), concurrent 
with completing their clinical training program. Such a model of supervision facilitates a 
broad training experience and a unique opportunity for mentorship from both clinical 
supervisors and basic researchers.    
Mixing and mingling - the role of conferences in the future. Finally, even amongst 
those clinical psychologists who do enter academia, there exist lamentably few forums for 
exchanging ideas with researchers from other disciplines, as the journals they read and 
conferences they attend are typically discipline-specific (with some notable exceptions e.g. 
the annual MQ: Transforming Mental Health annual science meeting; a recent meeting on 
neuroscientific research into psychological treatments arranged by the European College of 
Neuropsychopharmacology:https://www.ecnp.eu/publications/presidents_blog/April%202016
.aspx; and the annual meeting of the German Association for Psychiatry, Psychotherapy and 
Psychosomatics: https://www.dgppn.de/). However, in some cases clinical psychologists and 
neuroscience researchers have started to work together to produce new ideas for intervention. 
A good example is the adoption of ideas from the literature on the neuroscience of 
reconsolidation – the modification of old memories during their reactivation - in the 
formulation of new treatment approaches for PTSD260. Several studies have tested the 
possibility that reactivated memories could be disrupted through pharmacological 
intervention with propranolol261, 262, with some preliminary indications of positive effects. 
Other studies have tested whether the reconsolidation of established memories can be 
disrupted using simple psychological interventions based on cognitive science, with 
promising results. Engaging in a simple visuospatial task (the computer game Tetris) 
following memory reactivation was shown to substantially reduce subsequent intrusive 
memories of experimental trauma63. Although this line of research requires considerable 
further work to demonstrate robust clinical efficacy263, 264, (see Section 6, Trials), it is an 
intriguing example of the type of cross-pollination of ideas between basic and clinical 
research that holds promise to lead to improved treatments in the future. Other good 
examples are to be found in the development of new psychological interventions for 
anhedonia (see Panel 17). 
 
Conclusion 
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 In the 1950s and 60s the development of new psychological interventions transformed 
the landscape of mental health treatment, creating effective treatments based on novel, 
empirically testable models. Inspired by ideas drawn from cognitive psychology and 
behavioural neuroscience, the interventions developed through the collaborations of previous 
generations of basic researchers and clinicians have become today’s treatments of choice. 
Despite these successes, there is still great room for improvement as response to 
psychological interventions is highly variable; however, in recent decades the fruitful 
interaction between those who deliver psychological interventions and those who conduct 
basic research has waned. This gap impedes innovation in the development of new 
psychological treatments, both because basic researchers do not understand what 
psychological interventions entail, and because clinicians are not familiar with relevant 
advances. Above, we have outlined a number of concrete proposals with the aim of bridging 
this gap: these have in common the fostering of much more extensive interdisciplinary 
interaction and dialogue than currently exists, see also Panel 18. Through taking these steps, 
the next generation of clinicians and researchers will be better equipped than their 
predecessors to use new knowledge to drive the development of novel and more effective 
psychological treatments and preventative strategies that are needed to improve mental health 
outcomes. 
 
Panel 18.  Example Directions for the Future of Training and Links between Clinical 
and Basic Science 
 Opportunities for integrated clinical and academic training in psychology, through 
extended programmes, targeted at those clinicians with the greatest research 
potential 
 Training for basic researchers in psychological treatments, including hands-on 
experience of techniques, and interactions with clinicians, so that they can 
formulate research questions that are relevant to psychological interventions 
 An expectation of interdisciplinary research for psychological treatment 
researchers, including co-supervision of the research component of professional 
qualifications by clinical and non-clinical PIs  
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 Provision of “next steps” seminars focused on academic training as a standard part 
of mental health clinical training programmes 
 Better dissemination of research internship and doctoral funding opportunities for 
clinical psychologists, such as provided by the Society for a Science of Clinical 
Psychology (http://www.sscpweb.org/) 
 Training programmes on which clinical psychology, psychiatry and basic research 
trainees have the opportunity to learn alongside each other 
 High-level interdisciplinary meetings between basic researchers, clinical 
psychologists and psychiatrists, including forums in which practitioners can 
propose questions that they think are important to basic scientists; with tangible 
outcomes such as papers, grant applications, and implementation work 
 Use of the continuing professional development framework to enhance the 
understanding of basic science understanding among psychological treatment 
practitioners 
 
  
 
 
97 
 
 
8. Who should we treat for what and with what? Embracing the complexity of mental 
health conditions from personalised models to universal approaches 
 
Overview: Complexities 
Most theoretical models and evidence based psychological treatments have typically 
been derived for categorically defined specific mental health disorders, such as major 
depressive disorder, social phobia, or posttraumatic stress disorder. However, the reality of 
mental health conditions is more complex, and characterised by an enormous individual 
variety. Heterogeneity in symptomatology is very common and a substantial proportion of 
individuals suffering from mental health disorders have more than one disorder (co-
morbidity). Many more have sub-syndromal symptoms of other conditions, and may have 
symptoms that shift between disorders over time. Mental health researchers – and those in 
psychological treatment research specifically - need to embrace the complexity of mental 
health disorders to make further progress in reducing the burden of these disabling 
conditions. The complexity of mental health disorders is a challenge for research and clinical 
practice. Solutions to complexity of mental health disorders include both highly 
individualized ‘personalised’ approaches as well as ‘universal’/‘transdiagnostic’ approaches 
that target common mechanisms. However, more studies are needed to examine whether both 
of these approaches improve the effectiveness of treatments for mental health disorders.  
 
Introduction 
Leading clinical guidelines recommend specific treatments for each mental health 
disorder, usually categorically defined by symptomatologye.g.265,266. However, in clinical 
practice the reality is different. Heterogeneity in symptomatology across mental health 
conditions is very common267 and many individuals suffer from more than one mental health 
disorder (i.e., co-morbidity268, 269). 
 
Why are mental health disorders so complex?  
 Unlike most areas of medicine, mental health disorders are defined predominantly by 
their symptoms. Lack of knowledge about aetiology contributes to this approach. Symptoms 
are often considered as manifestations of an underlying latent factor (e.g., sad mood and loss 
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of interest is caused by an underlying Major Depressive Disorder, MDD). However, these 
symptoms may not (only) serve as output from ‘underlying’ processes, but the symptoms can 
mutually reinforce one other as presumed by the network approach270. For example, in 
depression, insomnia might lead to concentration problems, which in turn might cause 
sadness and loss of pleasure, which in turn might lead to fatigue, feelings of guilt and suicidal 
ideation, resulting in the full syndrome of MDD. Thus, it is uncertain whether these 
symptoms are indeed manifestations of an underlying factor270. 
Another reason that mental health conditions are more complex to study than physical 
health conditions is their dimensional nature. Yet, most mental health researchers make use 
of a categorical model that fits in most health care models to study the effects of treatments. 
The Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5271) is a categorical 
nosology for classification, to detect for instance a depressive episode and to study the effects 
of a disorder specific treatment for depression such as behavioral activation (see Section 18, 
for a definition of disorder-specific interventions). In the last few years, initiatives have been 
taken, for instance by the NIMH Research Domain Criteria (RDoC) Initiative, to stimulate 
research on dimensions of observable behavior and neurobiological measures instead of 
categorical diagnostic criteria of mental health disorders (see Section 1, NIMH Strategic 
Plan272). 
An additional complexity factor is individual differences at the level of 
psychopathology, whether it is categorical or dimensional. Studies using network analyses 
have yielded new insights in individual variation of psychopathology267, 273. These studies 
indicate that while for some the transition from feeling healthy to fully depressed can be 
abrupt (categorical) in case of a strongly connected network of symptomatology, for others, 
for example individuals with a weakly connected network of symptoms, external stressors 
(such as not being able to pay rent) may lead to an increase in symptomatology - but these 
symptoms gradually decrease after the stressor is gone274. This could also be explained by a 
dimensional model of psychopathology; that is, individuals with strongly connected networks 
might be the individuals with higher levels of neuroticism. It is unclear whether these 
individual differences can be explained by an underlying dimensional mechanism or 
categorical disorder. 
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Enormous individual differences have been found in emotional fluctuations – an 
important component of many mental health disorders - and how emotions change over time 
within mental health disorders275. Furthermore, mental health conditions are complex to study 
due to the interplay between individual emotions, cognitions and physiology (and other 
factors) and their interactions with environment. These interactions of cognitions, emotions, 
and biomarkers by environment change over time (see also Section 1, Mechanisms for the 
differentiation of mechanisms responsible for onset versus mechanisms that are responsible 
for maintenance of psychopathology), and might also change as a consequence of suffering 
from a mental health condition. For instance, in depression major life events are consistent 
risk factors for onset of the first episode (such as the death of a loved one), while less stress 
(for instance a daily hassle like getting a minor traffic ticket) is required to trigger a 
subsequent depressive episode for individuals who have experienced one or two previous 
depressive episodes276, 277. 
Further, a substantial proportion (at least 45%) of people suffering from mental health 
disorders have more than one disorder, i.e., co-morbidity (see Panel 19), while many more 
have sub-syndromal symptoms of other conditions268. The lifetime co-morbidity of common 
mental health disorders (i.e., anxiety disorders with major depressive disorder) rises up to 
73%269. The Global Burden of Disease Study 2013 estimated that co-morbidity for acute and 
chronic diseases and injuries for 188 countries between 1990 and 2013, including co-
morbidity of mental health conditions, has risen substantially278. Co-morbidity is consistently 
associated with a greater demand for professional help, a poorer prognosis, greater 
interference with everyday life, and higher suicide rates279-284. Better understanding of co-
morbidity is crucial for knowledge on etiology and to improve psychological treatments for 
all mental health disorders.  
Heterogeneity and co-morbidity have been considered in some fields285-290. 
Dimensional models have been proposed to explain co-morbidity, and mostly suggest shared 
factors for the concurrent disorders (such as neuroticism291), and some dimensional models 
add specific factors that differentiate among disorderse.g.291-293. For instance, the dimensional 
tri-level hierarchical model of anxiety and depression includes a shared higher level factor for 
anxiety and depression (i.e., general distress), two additional factors that are at an 
intermediate level in terms of specificity for anxiety and depression (i.e., anxious-misery and 
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fears that explain covariation in positive affect, anhedonia, sad mood and social fears and 
fears to explain covariation in social fears, fears of specific stimuli, fear of interoceptive 
sensations, and agoraphobic fears), and five additional specific unique factors for depression 
and anxiety disorders (depression, fears of specific stimuli, anxious arousal, social fears and 
interoceptive/agoraphobic fears)294. For example, as shown in Figure 1 the dimensional tri-
level hierarchical model of co-morbidity between MDD and generalized anxiety disorders 
(GAD) according to this model I (as indicated by the black boxes and black lines) is 
explained by general distress, and at an intermediate level by anxious-misery (e.g., anhedonia 
and depression), and at low level by specific factors (e.g., depression and anxious arousal). 
 
 
 
 
Figure 1. Co-morbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder 
(GAD) symptomatology explained by tri-level hierarchical model of depression and anxiety 
(based on294). Black boxes and lines represent factors and symptoms related to MDD-GAD 
co-morbidity. 
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Alternatively, the network approach explains co-morbidity by spreading symptom 
activations. Co-morbidity is hypothesized to result from direct relations between symptoms 
of multiple disorders. That is, a symptom of one diagnostic category (e.g., MDD) can evoke 
other symptoms that in turn evoke symptoms of another diagnostic category (e.g., anxiety 
about several events, chronic anxiety/worry)267, 270. Thus, co-morbidity might be the result of 
shared symptoms across mental health disorders, so called bridge symptoms.  
Figure 2 represents an example of a dynamic network of Major Depressive Disorder 
(MDD) symptoms that mutually reinforce other symptoms of MDD and co-morbid 
Generalized Anxiety Disorder (GAD) symptoms (adapted figure, based on270). Nodes 
represent symptoms and edges denote the presumed causal relationship between symptoms. 
Darker edges indicate a stronger relationship between the symptoms. For example, disturbed 
sleeping (symptoms of depression) could lead to fatigue and to concentration problems and 
irritability/agitation (so called bridge symptoms as indicated by red nodes) and other specific 
generalized anxiety disorder symptomatology. The bridge symptoms are criteria of MDD and 
GAD267, 270, 295. In addition, there may be individual differences in how co-morbidity 
develops resulting in many different paths to co-morbidity, depending on the individual and 
his or her environmente.g., 267, 270, 295. The network approach does not explain why some 
individuals are more prone to co-morbidity (having more symptoms) than others. 
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Figure 2. Hypothetical dynamic network of Major Depressive Disorder (MDD) symptoms 
that mutually reinforce other symptoms of MDD and comorbid Generalized Anxiety Disorder 
Symptoms (GAD, adapted from270). Nodes represent symptoms and edges denote the causal 
relationship between symptoms. Darker edges indicate a stronger relationship between the 
symptoms. Red nodes are bridge symptoms of MDD and GAD. 
 
Both the network model and the dimensional (hierarchical) models (for instance 
dimensional underlying factors like neuroticism or general distress) might contribute to the 
explanation of mental health disorders, including co-morbidity. They emphasize the necessity 
to translate group findings to the individual struggling with mental health problems. The role 
of symptoms, individual differences in symptoms and emotions and potential underlying 
mechanisms as maintenance factors in mental health disorders are key elements to study.   
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Panel 19. What is Meant by Co-Morbidity, Disorder-Specific versus Transdiagnostic 
Treatment, and Personalised Treatment Approaches? 
 Co-morbidity: two or more mental health disorders that are present during the same 
period of time (concurrent co-morbidity) or that are present during one’s life 
(lifetime co-morbidity)  
 Disorder-specific treatment: a treatment that has been developed and evaluated for 
a specific mental health disorder 
 Transdiagnostic/universal treatment: the use of similar treatment approaches across 
a range of symptoms/mental health disorders that target the presumed underlying 
shared maintaining mechanisms296  
 Personalised treatment: optimize the most efficient and favorable response to 
treatment based on individual’s unique characteristics and/or presumed underlying 
mechanisms 
  
Personalised models of mental health conditions 
Although some disorder specific treatments yield positive effects on co-morbid 
disorders as well (for instance cognitive behavioral therapy for specific anxiety disorders also 
reduce depressive symptomatology297), there is certainly room for improvement in terms of 
treatment outcomes for people with mental health disorders, including individuals with co-
morbid mental health conditions.  
Research should embrace the complexity of mental health disorders to make further 
progress in psychological treatments research. One way forward is to study both inter- and 
intra-individual differences. Experience Sampling Methods (ESM or Ecological Momentary 
Assessment) can be used to develop personalized models of psychopathology298. ESM refers 
to a collection of research methods by which a client repeatedly reports on symptoms, affect, 
behavior, and cognitions close in time to experience and in the clients’ daily life, for instance 
by using an application on a mobile phone (see also Section 5, Technology). Given that ESM 
gathers numerous assessments for each individual, individualised analyses can generate an 
individualised model on the dynamics of the network of psychopathology for each person. 
Hereby, for instance the centrality (or the strength) of a specific symptom or mechanism for 
one specific person can be defined (e.g., loss of interest may be a central symptom for one 
individual with MDD, while for another individual a central symptom could be sad mood)298. 
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This would offer new insights into mental health disorders and personalised models of 
psychopathology. Several recent systematic reviews have stressed the value of ESM for 
assessing symptom fluctuations and interactions over time in anxiety disorders299, depressive 
disorders300, and substance use301. Studying transient processes of emotions, cognitions, 
symptoms and stress (and other relevant factors) in daily life can be done both in prospective 
studies, as well as in experimental studies, such as a RCT (see Section 6, Trials). For 
instance, alongside a RCT of the effectiveness of three relapse prevention treatments in 
depression, an EMA study was incorporated in a subset of participants who had remitted 
from recurrent depression (N = 51). This EMA study involved assessing participants’ 
emotions, cognitions, symptoms and imagery-based processing ten times a day, three days a 
week, for eight weeks using the “Imagine your mood” Application on a mobile phone302. 
Given these EMA studies are self-report questionnaires, it may be useful to add physiological 
and behavioral measures to such investigations.  
Personalised treatment approaches 
Research on personalised models might disentangle the complexity of mental health 
conditions, including co-morbidity, and optimise psychological treatments (see Panel 19). 
The goal of the personal medicine approach is to optimise the most efficient and favorable 
response to treatment based on an individual’s unique characteristics (a wide range of 
characteristics ranging from genetic and neurobiological factors to symptoms) and underlying 
mechanisms (see Panel 19). EMA (i.e., assessing daily fluctuations of change over time 
within a person) might improve our insight into the specific diagnosis303,304 and also offer 
valuable information that might improve patient-treatment matching. For instance, assessing 
daily fluctuations in positive and negative emotions using ESM in depression predicts 
response to treatment in depression305. In addition, assessing individual change over time in 
emotions (and other processes) while undergoing therapy (for instance in the context of a 
randomized controlled trial) might offer valuable empirical information on patterns of change 
and mechanisms of change during treatment.  
An alternative route to improve patient-treatment matching is to use a machine 
learning approach to identify characteristics of the individual, based on group-based studies, 
which predict differential response to existing treatments using methods to transform 
predictive information for a specific person. A recent demonstration is the computation of a 
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Personalised Advantage Index score306 comparing psychological versus pharmacological 
treatments for depression. Future studies should examine whether treatment matching can be 
improved for the substantial group of individuals with comorbid mental health disorders. 
Related approaches include clinical risk scoring, as currently used within the medical field307. 
For example, treatments for lung cancer are further improved by molecular testing for 
targeted therapies that can overcome resistance to first-generation drugs308.  Within the field 
of mental health conditions we need more studies to examine the relevant variables for these 
index scores to optimize patient-treatment matching and incorporate the help of, for instance, 
machine learning.  
In addition, as described in Section 1 (Mechansims), research on mechanisms of 
psychological treatments might reveal crucial moderators of treatment outcome that leads to 
better patient-treatment matching, such as a biological marker (for instance larger effects of 
an attentional bias training in anxiety disorders for the group of individuals with a specific 
polymorphism of the serotonin transporter gene 5-HTTLPR). 
Apart from enhancing patient-treatment matching, feedback to the clinician and the 
patient on daily fluctuations might be used to adapt treatment and thereby improve treatment 
outcome(s). Feedback on daily fluctuations of change within a person might enable us to 
adapt the interventions immediately within the sessions by giving real-time feedback on the 
progress to the clinician as well as the patient277. For instance, a RCT in 102 depressed 
patients showed that the efficacy of pharmacological treatment could be enhanced by adding 
ESM-derived feedback on personalized patterns of positive affect to the clinician and the 
patient309. Collecting EMA data with comparable assessments within clinical settings (as 
suggested in Section 6, Trials) on patterns of daily fluctuation of change over time within a 
person while undergoing treatment in a large population with mental health disorders 
(including outcomes after treatment) would be of great value. Mobile devices and 
applications could increasingly be used for person tailored, in-the-moment interventions. In 
the future, researchers could make empirical data available to clinicians and patients, which 
may help them to work together on improving treatment outcome as a team. Close 
collaboration will be needed with computer science and mathematics, drawing on advances in 
these fields (for instance areas of complexity, dynamical systems, and dealing with big data). 
Future research is needed on the dynamics of symptom outcome rather than simply static 
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assessments, for example using time series analysis on of daily mood data in bipolar 
disorder310, and using the same method within the context of a randomized controlled trial. 
For now, more studies are needed to examine whether personalised treatments are indeed 
more effective than traditional treatments. A critical question for the coming years will be: 
can we personalise our psychopathological models to the level that we can adjust our 
treatment and thereby improve outcomes? (see Panel 20 and Section 6, Trials). 
One Size Fits All or a Universal Approach? 
Most traditional disorder-specific psychological treatments contain a package of 
several interventions that target underlying mechanisms of psychopathology (see section 1 on 
mechanisms of psychological treatments). Apart from traditional disorder-specific approaches 
and personalized approaches, the opposite – although not incompatible - approach is to 
consider commonalities between mental disorders and a more “universal” approach (see 
Panel 19). For example, adverse life events are consistent predictors of the onset of most 
mental health conditions311. A risk factor, for instance, stress sensitisation, might prove to be 
a valuable target for treatment, since changing sensitization might influence the other 
symptoms in the network as well, such as rumination or sleeping problems312. Alternatively, 
changing stress sensitization might reduce a latent factor (such as neuroticism) and thereby 
reduce symptomatology. We might focus research efforts on trying to identify universal 
underlying mechanisms across numerous mental health conditions, and try to target these 
mechanisms by universal interventions (see Panel 20). This transdiagnostic approach, for 
instance in eating disorders, has begun to yield very promising results 313, 314. 
Another example of a transdiagnostic psychological treatment approach is Barlow’s 
“Unified Protocol” for the transdiagnostic treatment of emotional disorders. This approach 
targets transdiagnostic mechanisms that are hypothesised to be responsible for the 
development and maintenance of psychopathology broadly, rather than addressing disorder-
specific mechanisms or symptomatology (especially studied in patients with a principal 
anxiety disorder)315. Within developments of this approach, a more personalised approach is 
included which assesses a personalised model for each patient’s dysfunction related to 
underlying mechanisms (profiling). The personal profile can be used to select additional 
interventions that are specific to the mechanisms underlying the patient’s symptomatology316. 
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More studies are needed that examine whether these unified approaches are indeed more 
effective than traditional disorder specific treatments.  
Despite the apparent contrast between a personalised versus universal approach, we 
suggest that the research agenda ahead needs to embrace complexity, including co-morbidity, 
and consider both ends of the treatment spectrum – i.e., to both examine approaches which 
could offer cross-cutting universal treatment approaches and, if necessary, add disorder-
specific interventions, alongside personalised treatment solutions (see Panel 19). Mental 
health researchers – and those who conduct research on psychological treatments specifically 
- should embrace the variety of complexities (including the enormous variety between 
individuals, as well as co-morbidity) that are inherent in studying mental health. Solutions to 
complexity of mental health disorders need to consider both highly individualised 
‘personalised’ approaches as well as ‘universal’ / ‘transdiagnostic’ approaches to target 
common mechanisms (see Panel 20).  
Panel 20. Example Directions for Future Research Regarding Complexities 
 Embrace the complexity of mental health disorders, including co-morbidity, by 
studying inter- and intra-individual differences in daily life: investigate individual 
processes of emotions, cognitions, symptoms and stress (and other relevant 
mechanisms) in prospective studies, as well as in experimental studies, such as a 
RCT 
 Study models that explain co-morbidity in mental health disorders and treatment 
approaches for co-morbid disorders  
 Investigate whether we can personalise our psychopathological models to the level 
that we can adjust treatments and thereby improve treatment outcomes 
 Investigate who we should treat with what: a disorder-specific treatment, a 
personalized treatment and/or transdiagnostic/unified treatment 
 Examine the effects of transdiagnostic/unified treatments for several mental health 
conditions including the co-morbid conditions in comparison to current evidence 
based disorder-specific treatments 
 
 
 
 
108 
 
 
  
9. Target: Suicidal behaviour: Protecting lives 
 
Overview: Suicide 
In this section we illustrate how many of the principles outlined earlier in the 
Commission could usefully be applied to the development, evaluation and implementation of 
treatments to reduce suicidal behaviour. Although the causes of suicide and suicidal 
behaviour are complex, they are psychological phenomena at their core as an individual who 
attempts suicide makes a decision to end their life. In the past 25 years, there have been 
significant advances in understanding who is most at risk of suicide and what factors 
increase this risk in some individuals but not in others. Moving forward, we can build upon 
the growing evidence base for psychological treatments to reduce the risk of suicidal 
behaviour. Despite these recent advances, however, there are key gaps in knowledge that 
require urgent attention. Addressing these gaps represents an excellent opportunity to 
develop more effective treatments that are replicable, more precise, and can reach those who 
are most vulnerable irrespective of who they are or where they live. 
 
Introduction 
Suicide and suicide attempts are the most tragic outcomes that result from our failure 
to effectively treat those with mental health problems. In this section we illustrate how many 
of the principles outlined earlier in this Commission can be applied to the development, 
evaluation and implementation of treatments to reduce suicidal behaviour.  Suicide is a major 
public health concern: at least 804,000 people die by suicide globally each year317. Given the 
scale of the challenge of suicide prevention, we are strongly of the view that suicidal 
behaviour warrants inclusion as a standalone section in this commission. Indeed, as the latter 
is a transdiagnostic phenomenon associated with a myriad of mental health problems, we 
believe that it is uniquely placed to be a ‘test case’ of how what we have learned elsewhere in 
this Commission can be applied to a specific problem. Indeed, it may well become a distinct 
diagnostic phenomenon in the future (as suicidal behaviour disorder was included in Section 
3 of DSM 5, in areas requiring further research). In addition, given that suicidal behaviour 
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research (which includes tailored psychological treatments research) attracts only a fraction 
of the funding that mental health research receives - and mental health research only receives 
6% of the total UK spend on health research, (MQ Research; 
https://www.mqmentalhealth.org/research/research-funding-landscape) - its standalone status 
is warranted. However, we do acknowledge that not all of the recommendations herein are 
directly applicable to suicidal behaviour. 
In addition to the personal tragedy associated with every death by suicide, the 
economic cost of suicide is enormous. In Scotland, for example, the economic cost of suicide 
in a single year was estimated to have been in excess of £1 billion in 2004318. Although the 
science of suicide research is still relatively new, there have been welcome advances in the 
understanding, treatment and prevention of suicidal behaviour in recent decades319, see Panel 
21 for key terms.  These advances include a better understanding of the common risk factors 
for suicidal behaviour320-323, evidence that some psychological treatments reduce suicidal 
ideation and behaviour324-331 and growing evidence that public health interventions are 
associated with reductions in suicide330, 331. In this section we describe the advances that 
relate to psychological treatments in more detail but also identify a number of urgent calls to 
action (see Panel 22). Although we focus on psychological treatments, we should also keep 
in mind how the principles outlined in this Commission can relate to the primary prevention 
of suicide.  
Panel 21. Suicidal Behaviour and Protecting Lives - What is Meant by Key Terms 
 Suicide refers to a death in which an individual intentionally ends their own life 
 Suicidal behaviour refers to thoughts and behaviours related to an individual 
intentionally taking their own life. These thoughts include suicide ideation, when an 
individual has thoughts about intentionally taking their own life; they also include 
suicide attempt, which refers to engagement in a potentially self-injurious 
behaviour in which there is at least some intention of dying 
 Consistent with the UK National Institute for Health and Care Excellence guidance, 
self-harm is defined as intentional self-poisoning or self-injury, irrespective of 
motive332 
 
 
 
110 
 
 
Although suicide most often occurs in the context of mental health disorder333, 334 
there is widespread recognition of the need to move beyond diagnostic categories in order to 
explain and treat suicidal behaviour335. In addition, the central role of psychological factors in 
the aetiology and course of suicidal behaviour is now well recognized323. Arguably, suicide is 
the cause of death that is most closely related to psychological factors given that an 
individual makes a decision to end their own life323. Despite advances in our knowledge, our 
ability to predict who is most likely to kill themselves is limited because we do not have 
sufficiently specific markers of suicide risk. For example, although depression is the disorder 
most commonly associated with suicide risk, less than 5% of people treated for depression 
die by suicide323, 336, 337. 
New psychological models of suicide have been developed which have identified 
more proximal and specific markers of suicide risk337-343 (see also Section 1, Mechanisms). In 
addition to the theoretical importance of identifying proximal markers of the final common 
pathway to suicidal behaviour, proximal markers are vitally important clinically and should 
be treatment targets. Specifically, constructs including defeat, entrapment, belongingness, 
burdensomeness, future thinking, goal adjustment, reasons for living and fearlessness about 
death323, 339-341, 344, 345 are among the key predictors of suicide attempts we have as yet, and 
should, therefore, be targeted in psychological treatments and suicide prevention activities 
more generally. To date, there has been insufficient focus on these suicide-specific 
psychological proximal markers. Moreover, we know little about which factors are 
responsible for the observed effectiveness of suicide prevention approaches (see also Section 
1, Mechanisms). Psychological treatment trials for suicidal behaviour should routinely assess 
theoretically-derived mechanisms (both psychological and biological) which may explain the 
treatment effect. A concerted focus on potential biomarkers, for example, salivary cortisol or 
the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), ideally tested in combination 
with other factors is also required346, 347.  
Evidence for psychological treatments and suicidality 
Psychological treatments reduce suicidal ideation and suicide attempts324, 326, 348 
although there is little evidence that they have a marked effect on subsequent suicide349. 
Indeed, suicide rates have stayed the same or have increased by more than 10% in 51% of 
172 member states of the World Health Organisation between 2000 and 2012317, including 
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the USA. So, one interpretation is that (if effective) the increased availability of 
psychological treatments should have contributed, in part, to a reduced suicide rate in these 
countries. Although that is one interpretation, given that most people who die by suicide are 
not in contact with clinical services in the 12 months before death, until we expand the reach 
of psychological treatments beyond those already in contact with clinical services, it is 
unlikely that their effectiveness will have a direct impact upon national suicide rates. 
Moreover, given the complexity of the risk factors for suicide, multilevel interventions offer 
most promise350 and psychological treatments on their own will not make a sizeable dent in  
suicide rates.  
Nonetheless, meta-analyses indicate that cognitive behaviour therapy (CBT) is 
effective in reducing suicidal behaviour in adults, although not in adolescents327. Indeed, this 
is consistent with a systematic review and meta-analysis of psychosocial interventions 
following self-harm in adults which concluded that CBT “seems to be effective in patients 
after self-harm” as is dialectical behaviour therapy for individuals with borderline 
personality351, and individual studies provide support for psychodynamic interpersonal 
therapy352 and mentalization-based therapy353 (although the need for replications of single 
studies is noted). Evidence for the collaborative assessment and management of suicidality 
(CAMS), a therapeutic framework for suicidality, is also growing354. More recently, there are 
encouraging findings for the attempted suicide short intervention program (ASSIP) which is a 
brief integrated therapy and personalized letters intervention355. However, the low number of 
intervention studies overall underscores the need to develop the research agenda in this area.  
A meta-analysis of therapeutic interventions for suicide attempts and self-harm in 
adolescents concluded that therapeutic interventions are effective in reducing self-harm 
(when it is treated as a global category which includes suicidal and non-suicidal self-harm), 
but that the effects are weaker when suicidal and non-suicidal behaviour are examined 
separately356. The latter is consistent with the newly published Cochrane review of 
interventions for children and adolescents who self-harm329. The review authors found 
relatively few trials (n = 11), most of which were single trials, from which they concluded 
that therapeutic assessment, mentalization, and dialectical behaviour therapy “warrant further 
evaluation”13 (see also Section 4, Prevention). Treatments that target depression are also not 
effective in reducing suicidal thoughts or attempts357. It is important to highlight that there is 
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marked heterogeneity across treatment studies in the field, that many studies have relatively 
small sample sizes and that there is clear evidence of publication bias with no published 
studies reporting negative findings327. Replications of the existing treatments by independent 
groups will strengthen the evidence base. The development of evidence-based assessment 
measures that are clinically useful is also lacking in the suicide treatment research field (see 
also Section 6, Trials). 
In brief, therefore, although the psychological treatments evidence-base for suicidal 
behaviour is growing, there are many gaps in knowledge. It is absolutely critical that the 
development, evaluation and implementation of psychological treatments for suicidality are 
prioritised. Moreover, we need to determine the extent to which psychological treatments are 
effective for different sociodemographic populations (males vs females, adolescents vs older 
adults, individuals from different ethnic backgrounds, etc.) as well as in different healthcare 
settings (e.g., primary/secondary care versus acute settings) and patient groups (e.g., 
psychiatric in- versus out-patients) (see also Section 8, Complexities). The former is 
especially important given that although more men die by suicide than women in all countries 
in the world, many more women participate in treatment trials. As a consequence, we do not 
know whether the existing treatments are effective for men. We also do not know whether 
treatments that have been shown to be effective in one setting generalize to other settings or 
patient groups. It is also not clear when it is optimal to deliver treatment interventions to 
reduce risk of future suicidal behaviour among those who have attempted suicide.  
Needless to say, psychological treatments are not a panacea. It is important to note 
that for those psychological treatments that are effective, overall the effect sizes have tended 
to be small358. This suggests, in part, that we require a better understanding of the 
mechanisms that comprise psychological treatments. Also, psychological treatments only 
reach a minority of people who take their own lives or who are suicidal (for many reasons 
including access and suitability). Given the established inequality gradient for suicide (people 
from lower socio-economic backgrounds are significantly more likely to die by suicide 
compared to their more affluent peers359), we need to challenge the structural inequalities 
(e.g., poverty) that contribute to the excess in suicide mortality evident in those from more 
socially disadvantaged backgrounds. 
Given that most suicides occur in low- and middle-income countries (LAMICs)317, the 
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extent to which treatments developed in high-income countries are generalizable to LAMICs 
needs very careful consideration (see also Section 2, Worldwide). When developing and 
evaluating treatment trials, consideration also needs to be given to whether a tailored or 
modular approach is desirable/feasible, whether the treatment is principles-based or 
manualized, and whether the interventions account for different risk profiles and inequalities 
(see also Section 8, Complexities). Even more fundamentally, though (as noted in Section 1, 
Mechanisms), we need to re-focus our efforts to ensure that we understand the mechanisms 
responsible for treatment successes when they do occur (e.g., does prevention of suicide 
depend on changes in reward sensitivity?). Without an understanding of mechanisms, our 
ability to tailor, target, extend and replicate treatments is limited. Indeed, an appreciation of 
mechanisms will help explain why treatments that are expected to be effective fail to be so. 
Furthermore, the identification of mechanisms will also improve precision in treatment-
matching. 
 
Challenges and opportunities for research   
The Calls to Action panel (see Panel 22) highlights the key challenges and 
opportunities for suicide treatment research in the next decade and beyond. As those who are 
at imminent risk of suicide are usually excluded from treatment trials, we know little about 
which treatments may be effective in this patient group. Relatedly, most people who are 
suicidal do not receive treatment360, therefore, we need to better understand the barriers to 
help-seeking or accessing treatment. It may be that people in distress are reluctant to seek 
psychological or psychiatric treatment for fear of stigma. Organisations such as Headspace 
(https://www.headspace.org.au) in Australia (see also Section 2, Worldwide) offer a promising 
stepped care treatment model which is low in stigma, set in the community and provides 
family members (as well as friends and health professionals) with an avenue to seek help for 
a relative. Another challenge is that suicidal patients are difficult to maintain in treatment361, 
so in addition to better understanding the factors associated with disengagement, we need to 
maximize treatment delivery when patients are in healthcare settings. For example, 
innovative brief contact interventions225, 362, 363 have been shown to offer some promise in 
acute settings. They should be considered as adjuncts to existing treatments and may be 
effective in reducing the likelihood that individuals act on their suicidal thoughts362, 363. 
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Although some public health suicide prevention interventions have adopted a multi-level 
approach and explored synergies (by delivering a combination of interventions364, 365), there 
are few examples of exploring synergies by combining different psychological treatments 
(see Section 3 on Combination Treatments).  Given the heterogeneity of those who attempt 
suicide or die by suicide, exploring the efficacy of treatment combinations is likely to be one 
fruitful avenue as we move forward. However, potential iatrogenic effects ought to be 
monitored in such studies (as well as in mono-treatment studies, see also Section 6, Trials). 
The potential for harm in psychological treatments has been highlighted in the Royal 
Australian and New Zealand College of Psychiatrists Guidelines for Deliberate Self-Harm358.  
We also need to focus on mechanisms and target those in developing new treatment 
approaches. 
To facilitate the pooling of findings across different treatment studies, we urge suicide 
researchers to agree on a common set of core outcome measures (see also Section 6, Trials).  
There has been some movement in this regard in the US325, however, an international 
consensus would be fruitful. To this end, it would be helpful to convene an international, 
interdisciplinary working group to agree such a set of measures. We also call for all 
psychological treatment trials to include a measure of suicidality as an outcome measure, 
even in studies in which this may only be a secondary focus. Although suicidal behaviour 
occurs transdiagnostically, we need to consider the differential prevalence of suicidal ideation 
and behaviour across psychiatric categories and better understand why, for example, 
individuals with bipolar disorder are at particularly high risk of suicide366. Psychological 
treatments research needs to embrace the assessment of potential mechanisms to account for 
treatment efficacy, as well as determine the active ingredients of effective treatments for 
suicidality (see also Section 1, Mechanisms). 
We also need to investigate the extent to which new technologies may be useful to 
engage so-called difficult to reach populations (e.g., men, adolescents)367, 368. For example, 
given the exponential growth in gaming, could this technology be harnessed to engage young 
people in help-seeking and treatment? As the roll-out of Internet-based psychological 
treatments continues, it is vital that they are developed with the same rigor as traditional 
means of psychological treatment delivery. Mobile apps also offer potential opportunities to 
monitor suicidal ideation and mood in real-time and have the potential to enhance our ability 
 
 
115 
 
 
to identify (and intervene) when individuals are at their most vulnerable (see also Section 5, 
Technology). Arguably, the field of suicide prevention has not given due consideration to the 
cultural influences and pressures (e.g., depictions of masculinity) on men and women. Given 
the scale of male suicide, it is vital that we better integrate such factors into our 
understanding of suicide risk as well as suicide prevention efforts in particular369-371.  
Those with lived experience of suicidal behaviour (e.g., individuals bereaved by 
suicide, and those with personal experience) should be involved in all stages of treatment 
development372. Consistent with other areas of psychological treatments research, as we 
know relatively little about what protects vulnerable people from engaging in suicidal 
behaviour, research into potential buffering factors should be central to the development of 
treatment protocols (see also Section 4, Prevention). 
Finally, team science is key to the success of developing, evaluating and 
implementing psychological treatments to prevent suicide. As suicide is the end-product of 
the interplay between psychological, social, biological, clinical and cultural factors, 
interdisciplinarity should be the norm in psychological treatment research (see also Section 7, 
Training).  However, given - as stated at the beginning of this section - that an individual 
makes a decision to end their life (in the context of a range of different risk factors), 
psychology needs to be at the centre of future developments in the field.  
To conclude, this is an exciting time to be working in psychological treatment 
research for suicide, as we have the theoretical and empirical foundations for promising 
treatments.  In the next decade and beyond, however, we have to be innovative in our 
thinking and practice, to ensure that the promise of psychological treatments research is 
realized and leads to a reduction in suicidal ideation and suicide attempts. 
 
Panel 22. Calls to Action for Psychological Treatments Suicide Research 
 More large-scale psychological treatment trials (including psychotherapeutic 
and brief contact interventions) targeting suicidal ideation/behaviour are 
urgently required 
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 Determine whether psychological treatments work for different 
sociodemographic populations (males vs females, adolescents vs older adults, 
individuals from different ethnic backgrounds etc) as well as in different settings 
(e.g., primary/secondary care versus acute settings), patient groups (e.g., 
psychiatric in- versus out-patients) and countries (e.g., low- middle-income 
versus high-income countries) 
 More rigorous investigation of those at imminent risk of suicide 
 Conduct replications of psychological treatments by independent groups 
 Agree on common measures of core outcomes (suicidal ideation and behaviour) 
and conduct multi-centre treatment studies and harness ‘big data’ techniques to 
determine whether psychological treatments can prevent suicide 
 Assess potential mechanisms derived from psychological theories hypothesized 
to account for treatment effects in all trials (risk and protective mechanisms) as 
well as moderators of the effects 
 Use techniques derived from experimental psychopathology to determine 
whether hypothesized mechanisms account for changes in symptoms or 
wellbeing (see Section 1, recommendations for identifying potential 
mechanisms) 
 Determine active ingredients of psychological treatments (including the role of 
therapeutic alliance) 
 All psychological and social treatments (irrespective of whether suicidality is 
the target) should include a measure of suicidal thinking/behaviour which could 
be harvested in ‘big data’ analyses  
 Determine the barriers to treatment seeking in men, in particular 
 Investigate the extent to which new technologies may be useful to engage 
difficult to reach populations (e.g., men, adolescents) 
 Those with lived experience of suicidal behaviour (those bereaved by suicide, 
those with personal experience) should be involved in all stages of 
psychological treatment research 
 
 
 
117 
 
 
10. Trafalgar Square and The Empty Plinth - A space for active innovation and 
scrutiny of psychological treatments research of the future 
 
Inspecting ideas - and making space for ideas of the future  
Psychological treatments are highly effective for many patients but a large proportion 
either fail to respond to existing therapies, or the therapies that we have cannot reach them. 
To ‘see further’ footnote#4 we need to innovate. To innovate, we need to generate ideas, and we 
need to engage in the critical inspection, progression as well as rejection of ideas, via the 
process of high quality, rigorous research.  
Psychological treatment research needs to harness, innovate, and provide a 
counterforce against stagnation, while preserving ideas that stand the test of time. In the 
Introduction, we used the metaphor “The Fourth Plinth” in Trafalgar Square. This empty 
plinth is used for a series of temporary works of contemporary art by leading national and 
international artists. Ideas are of their time and are selected, then replaced. Some pieces will 
be preserved for longevity, others may not. A plinth here is a metaphor to make 
contemporary ideas visible and to give them critical consideration. Particular psychological 
treatments and/or research ideas should not stand on a plinth forever. Rather, numerous ideas 
need to be generated, inspected and replaced over time, all within the context of a science-
driven framework. Psychological treatment is a relatively young field, and the notion of 
innovation and turnover are critical parts of its future. 
 How might this work for psychological treatments? Let us consider the wide range of 
potential topics, how they could be selected, where they would be aired, how they could 
achieve visibility, and the need for a repeated cycle of this endeavour - with the ultimate aim 
to better air and debate the issues of our time in order to make a difference for mental health. 
Topics could include both novel ideas or longstanding challenging topics. Novel issues could 
include recent findings that would benefit from constructive and rapid scrutiny (such as 
therapeutic approaches that emerge from the findings of pre-clinical studies, new ideas from 
                                                          
Footnote #4 “If I have seen further it is by standing on ye shoulders of Giants”; Letter from Isaac 
Newton to Robert Hook dated 5th February 1676, as transcribed in The Correspondence of 
Isaac Newton. (1959). H. W. Turnbull, Ed.  (Vol. 1.) Cambridge: Cambridge University 
Press. 
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sister disciplines, technology and new ethical issues, and so forth). Exciting new directions 
that emerge in these and other contexts should be clearly formulated, considered and reflected 
upon – and most importantly, need to be subjected to rigorous debate within and beyond the 
field, as well as empirical evaluation in the context of scientifically-sound studies such as 
well-controlled RCTs.  
 Open and constructive debate needs to be encouraged, without new ideas being too 
swiftly “smashed down” by tradition and vested interests in maintaining the status quo. On 
the other hand, new ideas and vogues in thinking (for example, fashionable new forms of 
therapy) must be scrutinised prior to being accepted and delivered in clinical practice. Of 
note, one problem for our field is the need to sustain the adoption of evidence-based 
treatments by practitioners, who may rather cast the evidence aside for techniques for which 
they have a personal preference. For example, “exposure” is a theoretically-driven treatment 
technique with an excellent evidence-base and for which there is a strong scientific 
understanding of the mechanisms that underlie its effectiveness (see Section 1, Mechanisms). 
However, in practise a substantial proportion of therapists do not use this effective 
therapeutic technique373. This reluctance and lack of uptake of empirically-supported 
interventions, or aspects of them, is an issue that needs to be understood and rectified. To use 
the metaphor, we should continue to work on improving some older statues on solid plinths, 
moving them from an empty plinth to a more permanent venue when appropriate. 
The plinth metaphor also provides a way in which to question older ideas that we now 
take for granted, and yet would benefit from further examination. There are many broader 
issues that affect the whole psychological treatment field which require discussion (such as 
our diagnostic systems, the quantity of academic publications versus their capacity to deliver 
patient impact, funding issues that are specific to psychological treatments, etc) as well as 
many issues that are currently relevant to science more generally - from reproducibility to 
open data. Psychological science is a young discipline compared to many other fields - 
further emphasis on the history of psychological treatments over the last century could be of 
benefit here. We note that there are parallels between some of our suggestions here and the 
‘Science in Transition’ initiative in the Netherlands, which calls for a number of key reforms 
in science with the goal of scientists producing reproducible outcomes374,375. 
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How can topics be selected? In the art world, the “Empty Plinth” is an open 
competition from artists and subject to a review panel – the winner places an object up on a 
platform for viewing and discussion. For psychological treatments research, there could be 
equivalent competition/selection process of having specific calls for people to raise 
challenging ideas which catalyse progress. This will generate topics beyond that what we can 
imagine now, and potentially create a way to capture the concerns and questions of younger 
generations in our field (e.g., why isn’t neuroscience being used more?), or those of 
researchers with several decades of experience (e.g., why have effect sizes for psychological 
treatments not improved?).  
The potential locations of where the “Empty Plinth” metaphor could be used could 
include a dedicated session at conferences and cross-disciplinary meetings, a type of journal 
article, in electronic media and so forth in areas which allow debate and scrutiny. Clearly the 
field does not have one place such as London’s Trafalgar Square in which a metaphorical 
plinth would stand; rather, the metaphor could be adapted to fit the range of outlets, and 
journal editors and conference organisers alike could be encouraged to provide space for this. 
In order to bring attention to the resulting ideas, an annual prize could be awarded for topics 
that have attracted attention and made constructive progress.  
The Plinth metaphor highlights the need for repetition in this process – so that novel 
psychological treatment ideas displayed in the Plinth will constantly be generated, tested, and 
disseminated (as indicated). This iterative process will not only encourage innovation, but 
will enable differentiation of those new treatments and ideas that will stand the test of time – 
and allow long held assumptions to be questioned in order to bring about progress. In some 
sense these are all processes that occur throughout the scientific process. But as we have 
argued throughout this commission, due to the scale of mental health problems, progress 
needs to speed up for psychological treatments research and borrowing an idea from the Arts 
may be just one way to catalyse this. 
The early stage of our field (compared to many other scientific disciplines, e.g.,  
medicine, biology, physics) also offers opportunities. Mental health and psychological 
treatments provide critical, fascinating and demanding targets for research enquiry. Creative 
but realistic solutions require communication, and meaningful multidisciplinary 
collaborations among researchers and funding agencies, and some ‘blue skies’ thinking from 
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outside the field. More psychological treatment researchers are needed across all disciplines – 
there remain a vast range of important questions that as yet have barely been addressed. This 
poses a great opportunity for example for many early career scientists to make landmark 
contributions, and more should be encouraged to the field (see Section 7, Training).  
Stagnation versus innovation: the need for new treatments 
Arguably, psychological treatment research has stagnated. Outcomes for many 
psychological disorders (including depression, obsessive compulsive disorder, 
schizophrenia and bipolar disorders) have not improved since the interventions were 
developed, and may even be falling376. While there are notable exceptions of disorders from 
which lessons can be learned such as for eating disorders377, and others which are beyond the 
scope of this piece to list here, clearly more rapid advances are needed in numerous areas.   
There is an understandable current emphasis on increasing access to existing 
psychological treatments98 given the large unmet need and changing models of service 
delivery5,93,378,379 (see Section 2, Worldwide).  Relatedly, there are attempts to improve the 
efficiency of existing interventions via identification of mechanisms of treatment (see Section 
1, Mechanisms) so that that existing interventions can benefit more patients. There is, 
however, an equally strong need to develop innovative new psychological treatments for 
the large proportion of people who do not engage with or respond to existing 
interventions, or who relapse after a seemingly successful course of treatment. The 
proportion of people who fall into one of these categories varies by disorder, age group and 
research study, but can be considered to be at least 50%380, 381. Given the large number of 
people for whom psychological treatments are not sufficiently effective to make a tangible 
difference to their lives, there is an urgent requirement to develop new treatments. The 
development of such treatments will be challenging for practical reasons (such as cost), as 
well as conceptual ones: it is hard to ‘think differently’ from within an existing and agreed 
framework. Existing organisations that are designed to facilitate improvement and innovation 
(such as NHS Improving Quality in the UK) will be helpful, as will initiatives such as 
‘Science in Transition’. The ‘Science in Transition’ initiative arose in the Netherlands and 
proposes that Science has ‘gone wrong’ and is in need of fundamental reform with an 
increased focus on real societal relevance with a modified reward system that creates 
reproducible and translatable research374, 375. New treatments will require new research 
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processes and methods combined with a strong determination and energy to make 
change a reality.  
 Whilst we have called for the need to develop new psychological therapies in order to 
address the prevalence of and global burden imposed by mental health problems, we also see 
a pressing need for multiple solutions, given the scale of the challenge before us. We foresee 
value in a range of approaches, including the dissemination of evidence-based therapies, 
initiatives to reduce stigma, and increasing the accessibility of evidence-based 
psychotherapies (e.g., through internet interventions or the training of lay-health counsellors 
in low and middle income countries). So whilst we see the need for a multi-pronged 
approach, we argue that the development of new therapies is one of the most promising 
approaches - given the scale of the problem of mental health disorders from a public health 
perspective. 
 
What factors might foster stagnation and what innovation? Branding, communication and 
funding 
It is striking how the majority of psychological treatment researchers stick to 
what they know. Such adherence is rewarded by strong CVs, grant funding and an 
unparalleled deep knowledge of a field. However, it can also lead to insularity. Fields that are 
highly relevant to psychological treatments from not only neuroscience, maths and 
pharmacology (as discussed earlier), but a diverse range disciplines such as ‘medical 
geography’382 could help clinical researchers and practitioners think differently. 
Communicating with colleagues in other areas of science and bringing their learning into our 
psychological treatments has huge potential. Jointly reviewing advances in areas such as 
cognitive and social science to identify which innovations will be relevant to improving 
psychological therapies is entirely feasible. Such an approach has tremendous  potential to 
facilitate the introduction of new, scientifically sound ideas into treatment. 
One obstacle to innovation in the field of psychological treatment research is 
‘branding’ of psychological interventions, with the accompanying restrictions due to 
intellectual property issues. Such ‘branding’ prevents the dissemination and implementation 
of psychological therapies, and also stifles innovation by implying ‘ownership’ of an 
intervention383. A sustainable, not-for-profit model for the development of psychological 
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interventions is an alternative and potentially better way forward. The increasing pressure 
from ‘knowledge transfer’ departments at Universities for branding for uniqueness by one 
research group needs to be resisted where useful in favour of developments in psychological 
therapies that are more open, highlight shared common components, and are precisely 
described at a level at which they can benefit from examination by the wider the 
psychological treatment community. The issue is clearly complex due to concerns with 
regard to incentivising investment in psychological treatments from a range of sources, as 
well as the need for quality control within particular interventions. The development of 
‘citizen science’ has the potential to counteract branding and provide a fertile ground for 
innovation. Examples need to be developed and shared. 
Communication between clients, clinicians and across the health services as a 
whole needs improvement. As an example, mental and physical healthcare services are 
typically entirely separate services with minimal overlap, despite their close relationship in 
terms of pathology, service use and cost to the health services around the world384. Improving 
communication between providers of these two services via shared training, resources or 
even co-location will be a fundamental step in innovation, with scope to yield significant 
benefits for the entire healthcare system. Drawing on multiple areas of expertise will be 
important; in particular, obtaining input from patients and carers – a topic that is receiving 
increasing attention (see385, but requires more.  
It is impossible to divorce the issues of innovation and improvement from those 
of dissemination and implementation. Innovations that stay localised will benefit some 
patients but the impact will be minimal (see Section 2, Worldwide). Furthermore, the length 
of time from ‘bench to bedside’ (currently estimated at 17 years, although some argue it will 
be quicker to develop psychological than pharmacological treatments3,386) will continue to be 
unacceptably high unless dissemination and implementation are part of the plan from the 
outset (see also Section 5, Technology). Communication between stakeholders is essential to 
ensuring the impact of innovations. It is only through the development of meaningful 
networks that genuine collaborations can be built – such as joint training, joint conferences 
and joint funding. Such networks need to be funded appropriately for the stage of 
development, with basic researchers and clinicians having a bi-directional conversation, 
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initially by email but then face-to-face in a relaxed atmosphere with time to think creatively, 
argue constructively and develop testable hypotheses.   
The role of funders in promoting or stifling innovation cannot be 
overemphasised. The NIMH’s influence on funding has been profound, and inclusion of an 
‘other’ category on the RDoC387 (see also Section 1) so that researchers are not restricted to 
only studying the known has the potential to facilitate new ideas. While researchers 
understand that funding agencies have a tendency to be risk averse, the funding of high risk 
studies is fundamental to the development of new treatments. More support akin to the 
funding of psychological therapies by ‘MQ: Transforming Mental Health’ for proof of 
concept studies in psychological therapies could be especially important to the field. 
However, the level of funding for mental health research internationally, and psychological 
treatments in particular is far too low388, 389. As has been argued elsewhere – and needs to 
continue to be argued - increased funding is essential for progress. 
Globally, within larger funding organisations, mental health is often subsumed with 
other diseases or with for example, neuroscience. Representation by people with mental 
health research experience can be thin. Genuine expertise in mental health is needed on the 
decision making bodies of the major funding bodies. Clearer representation of expertise in 
psychological treatments would also be of benefit. It would be useful to have a review of 
international funding organisations which address mental health, and to determine the extent 
to which psychological treatment research is included and accommodated.  Some charities 
fund research and this is of course welcomed, but unfortunately many smaller charities often 
do not have the capacity to conduct a research review process that is as rigorous as that which 
can be carried out by larger, well-established, well-connected national charities or research 
bodies. A number of factors may be responsible, including a lack of infrastructure to support 
peer review, lack of knowledge of the peer review process). The quality and impact of studies 
that fail to benefit from peer review and scientific support is often sub-optimal. Funding 
models whereby smaller charities supporting mental health research are supported by larger 
charities with regard to their commissioning and execution of research is likely to improve 
both the quality of research and value for money of the research project. The creation of a 
framework for peer review for mental health in general, and psychological treatment in 
 
 
124 
 
 
particular – or even a possible outsourcing model for such processes – might help many 
organisations with funding initiatives in the area.  
 
How can we assess the effectiveness of our efforts? 
 Our broad aim in undertaking this commission was to identify ways in which research 
efforts have scope to improve mental health globally via advancements in the effectiveness 
and the global reach of psychological treatments. More specifically, we have outlined an 
agenda of some of the concrete areas in which we see real scope for improvements in 
treatment research and their delivery to translate to more effective interventions, and greater 
accessibility of such treatments, to individuals with mental health difficulties. Treatment 
protocols that more effectively treat, as well as prevent the onset of, mental disorders will in 
turn have a part to play among the many contributions needed to relieve the substantial 
worldwide burden imposed by mental ill health. 
 Our capacity to assess in a tangible and meaningful way whether the goal of 
improving mental health treatments has in fact been achieved remains a challenge for the 
field. The initial indicator of success on this front is at the level of trial outcomes – i.e., to 
examine whether effect sizes indicate improved efficacy of novel and refined psychological 
interventions. In the longer term, meta-analyses will delineate whether newer treatment 
approaches have made substantial gains in terms of improved effectiveness – and thus in turn, 
contribute to reducing the prevalence and indeed the burden of mental health problems. In the 
more distant future, the findings of epidemiological studies that illustrate rates of prevalence 
over time will speak to the success of treatment and prevention approaches. We 
acknowledge, however, that ‘measurement’ in this domain is indeed complicated and 
ambitious; e.g., changes in our diagnostic classification systems complicate these types of 
comparisons over time. We therefore see a need for research on how to define and quantify 
burden. We see scope for further progress to be made in not only examining prevalence rates, 
but also by investigating improvements in the functional impact of mental diseases, from 
impairments in social and occupational functioning through to quality of life (e.g., using 
instruments such as WHODAS 2.0390). Such a suggestion chimes with our earlier 
acknowledgement of the value of expanding conceptualizations of mental health beyond the 
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notions of disease and infirmity to outcomes with broader functional relevance (e.g., an 
individual’s capacity to adapt, self-manage, etc; see Introduction). 
 
Innovation to create new treatments. What ideas can we cast on the plinth in the first round?  
Increasing access to existing effective psychological treatments is a priority, but it is 
equally important to invest in innovations that will energise the field of psychological 
treatment research and improve therapeutic outcome5, 93. There are many books and journal 
articles dedicated to the issue of innovation, and even an entire journal devoted to this topic 
(‘Healthcare: The Journal of Delivery Science and Innovation’), which commenced in June 
2013. It is clear that innovation is a challenging area and that what is presented as innovation 
can often be seen as ‘old wine in a new bottle’. Innovation needs to be put in its historical 
context so that existing ideas are not repackaged with enthusiasm as an innovation391. As said, 
we need to engage in the critical inspection, progression as well as rejection of ideas via 
research;  that is, to celebrate a metaphorical plinth with replenishing ideas, rather than to 
imagine therapy-brand statues which stand for ever. One approach is to change the nature of 
the questions are asking. Here we begin with two examples. 
 
What matters to patients?  
Arguably, most clinical research has focussed on single diagnoses despite the fact that 
many patients experience multiple co-existing disorders392 (see Section 8, Complexity). 
Clinicians have guidelines for the treatment of specific diagnoses but almost no data to guide 
them with regard to evidence-based decision-making in cases where patients have common 
co-occurring disorders such as anxiety and depression. Patients’ difficulties can alternatively 
be considered in terms of the problem they are experiencing rather than in diagnostic terms, 
for example ‘loneliness’, or ‘betrayal’393. Linking with social psychology and having a 
problem-based approach to the development of psychological treatments, rather than a 
disorder-based approach, is likely to lead to new ways of thinking about, and addressing, 
mental health disorders, which was partly the intention of the RDoC387. Such approaches may 
increase engagement in and the acceptability of therapies, but would still have their 
challenges in terms of agreeing operationalised definitions of the problem, as well as ensuring 
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that such difficulties were impacting on people’s lives, interfering with functioning and could 
be viewed within a psychological framework. 
 
What matters to researchers?  
Many things matter to researchers - but most scientists become curious about what 
does not work, not just what does. Data that do not obey ‘the rules’ are essential to scientific 
progress. For psychological treatments research, defining non-responders, identifying which 
people relapse, as well as those who fail to engage in treatment - are all necessary and critical 
steps that will enable our field to progress381. Conducting a thorough and focused analysis of 
the characteristics of those individuals who do not respond to existing treatments, and having 
dedicated funding for such research, are priorities that would have a positive impact and 
would bring generalizable benefits to existing as well as new treatments.  
 
What next?  
We see mental health as a significant global challenge, but at the same time recognise 
that in current times we are faced with an array of pressing priorities that demand global 
attention and action; including but in no way limited to climate change, international 
conflicts, famine, and the displacement of millions of people from their home country. 
Notwithstanding the fact that many such significant problems exist in our world today, in the 
domain of mental health, we call for increased research efforts in order to evolve 
psychological treatments, so that more effective interventions will serve as an important part 
of our armoury of approaches needed to make a significant impact upon the burden of mental 
disease worldwide. 
We acknowledge that our call for developments in psychological treatments for 
mental health problems is but one endeavour in the context other timely such initiatives. For 
example, Wykes et al.394 recently laid out six key priorities for a mental health research 
agenda for Europe and worldwide. Mental health is increasingly being recognised as a 
domain in which we need to move forward on a global scale. Furthermore, psychological 
interventions can be applied not only to mental health problems, but have been increasingly 
utilised across a range of areas; for example, in promoting health behaviour change, 
managing the psychological aspects and impact of physical health problems (e.g., pain 
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management and somatic concerns, psycho-oncology), instituting organisational change, to 
name just a few. 
 
Clinicians, researchers, patients, carers, funders, commissioners, managers, policy-
planners, ‘change’ experts and the wider public all have a part to play in innovating 
psychological therapies and a focus on any one of the above ideas presented in this paper has 
the potential to bring about dramatic and much-needed improvements. Such innovations have 
genuine potential to transform the science and practice of psychological therapies, as well as 
the lives of all of those affected by mental health problems.  
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Figure. The Forth Plinth, Trafalgar Square London, from different angles (photo by E. 
Holmes, 2016) 
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